ImmunityBio, Inc. 10-K

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report s of Independent Registered Public Accounting Firm (PCAOB ID: 34 ) 161 Report of Independent Registered Public Accounting Firm (PCAOB ID: 42 ) 163 Consolidated Balance Sheets as of December 31, 2025 and 2024 164 Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 166 Consolidated Statements of Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023 167 Consolidated Statements of Stockholders’ Deficit for the years ended December 31, 2025, 2024 and 2023 168 Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023 171 Notes to Consolidated Financial Statements 174 160 Table of Contents REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the stockholders and the Board of Directors of ImmunityBio, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of ImmunityBio, Inc. and subsidiaries (the “Company”) as of December 31, 2025, the related consolidated statements of operations, comprehensive loss, stockholders’ deficit, and cash flows for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 23, 2026, expressed an unqualified opinion on the Company’s internal control over financial reporting. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. Critical Audit Matter The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. Related-party convertible note, at fair value — Refer to Note 2 and Note 14 to the financial statements Critical Audit Matter Description As of December 31, 2025, the Company had a related-party convertible note (the “Convertible Note”) with a principal amount of $505 million. The Company elected the fair value option to account for the Convertible Note and measured the Convertible Note at fair value at each reporting period. The Company estimated the fair value of the Convertible Note using a binomial lattice model, a complex modeling tool, at each reporting period. The model incorporates inputs such as the Company’s stock price, risk-free rate, expected volatility, and expected market yield. The expected volatility and expected market yield involve unobservable inputs. 161 Table of Contents Unlike the fair value of financial instruments that are readily observable, the valuation of the Convertible Note is inherently subjective and involves the use of complex modeling tools. Auditing the fair value required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists. How the Critical Audit Matter Was Addressed in the Audit Our audit procedures related to the valuation of the Convertible Note included the following, among others: • We evaluated the design and operating effectiveness of the internal control over the valuation of the Convertible Note. • With the assistance of our fair value specialists, we evaluated the reasonableness of management’s valuation methodology and the significant assumptions used in determining the fair value of the Convertible Note by: ◦ Inspecting the underlying contracts and evaluating the appropriateness of the valuation methodology based on the contract terms. ◦ Testing the source information underlying the fair value of the Convertible Note and the mathematical accuracy of the calculations. ◦ Developing independent estimates of the inputs and comparing those inputs to those used in the Company’s calculation of the fair value of the Convertible Note. • We evaluated the competency and objectivity of management’s expert engaged by the Company to perform the valuation of the Convertible Note. /s/ Deloitte & Touche LLP San Diego, California February 23, 2026 We have served as the Company’s auditor since 2025. 162 Table of Contents Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of ImmunityBio, Inc. and Subsidiaries Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of ImmunityBio, Inc. and Subsidiaries (the Company) as of December 31, 2024, the related consolidated statements of operations, comprehensive loss, stockholders’ deficit and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. /s/ Ernst & Young LLP We served as the Company’s auditor from 2016 to 2025. Los Angeles, California March 3, 2025 163 Table of Contents ImmunityBio, Inc. and Subsidiaries Consolidated Balance Sheets (in thousands, except share and per share amounts) As of December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 88,334 $ 143,428 Marketable securities 154,484 6,381 Accounts receivable, net 42,571 2,360 Inventories 910 8,272 Due from related parties 46 293 Prepaid expenses and other current assets 27,761 20,872 Prepaid expenses – related parties 769 2,980 Total current assets 314,875 184,586 Property, plant and equipment, net 114,264 137,094 Goodwill and intangible assets, net 13,953 15,933 Long-term inventories 13,508 — Convertible note receivable 7,380 7,130 Operating lease right-of-use assets, net 19,808 17,407 Operating lease right-of-use assets, net – related parties 13,202 15,956 Other assets 4,530 4,449 Other assets – related parties 378 378 Total assets $ 501,898 $ 382,933 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable $ 6,978 $ 6,725 Accrued expenses and other liabilities 46,838 40,580 Operating lease liabilities 4,291 4,005 Operating lease liabilities – related parties 3,244 3,461 Due to related parties 403 173 Total current liabilities 61,754 54,944 Related-party convertible note payable, at fair value ( Note 14 ) and ( Note 23 ) 477,093 461,877 Revenue interest liability ( Note 13 ) 324,615 284,404 Operating lease liabilities, less current portion 19,732 17,864 Operating lease liabilities, less current portion – related parties 13,715 16,959 Derivative liabilities ( Note 13 ) 19,722 26,120 Warrant liabilities ( Note 16 ) and ( Note 23 ) 84,417 8,575 Other liabilities 424 319 Total liabilities 1,001,472 871,062 The accompanying notes are an integral part of these consolidated financial statements. 164 Table of Contents ImmunityBio, Inc. and Subsidiaries Consolidated Balance Sheets (Continued) (in thousands, except share and per share amounts) As of December 31, 2025 2024 Commitments and contingencies ( Note 11 ) Stockholders’ deficit: Common stock, $ 0.0001 par value; 1,650,000,000 and 1,350,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 1,011,800,008 and 852,904,340 shares issued and outstanding as of December 31, 2025 and 2024, respectively; excluding treasury stock, 163,800 shares outstanding as of December 31, 2025 and 2024 $ 101 $ 85 Additional paid-in capital 3,197,120 2,884,867 Accumulated deficit ( 3,726,646 ) ( 3,375,248 ) Accumulated other comprehensive income 28,956 1,198 Total ImmunityBio stockholders’ deficit ( 500,469 ) ( 489,098 ) Noncontrolling interests 895 969 Total stockholders’ deficit ( 499,574 ) ( 488,129 ) Total liabilities and stockholders’ deficit $ 501,898 $ 382,933 The accompanying notes are an integral part of these consolidated financial statements. 165 Table of Contents ImmunityBio, Inc. and Subsidiaries Consolidated Statements of Operations (in thousands, except per share amounts) Year Ended December 31, 2025 2024 2023 Revenue Product revenue, net $ 112,982 $ 14,150 $ — Other revenues 306 595 622 Total revenue 113,288 14,745 622 Operating costs and expenses Cost of sales 753 — — Research and development 207,875 182,230 223,018 Research and development – related parties 10,684 7,914 9,348 Selling, general and administrative 147,180 165,801 126,136 Selling, general and administrative – related parties 2,823 2,982 3,484 Impairment of intangible assets — — 886 Total operating costs and expenses 369,315 358,927 362,872 Loss from operations ( 256,027 ) ( 344,182 ) ( 362,250 ) Other income (expense), net: Interest and investment income, net 6,405 7,975 1,131 Interest expense – related party ( 60,886 ) ( 114,588 ) ( 128,848 ) Interest expense related to revenue interest liability ( 51,540 ) ( 39,657 ) ( 264 ) Change in fair value of warrant liabilities 49,089 19,955 ( 47,600 ) Change in fair value of related-party convertible note ( 42,773 ) 43,472 ( 36,203 ) Change in fair value of derivative liabilities 6,398 13,477 — Interest expense ( 99 ) ( 82 ) ( 86 ) Loss on equity method investment — — ( 7,549 ) Other expense, net ( 2,174 ) ( 15 ) ( 2,223 ) Total other expense, net ( 95,580 ) ( 69,463 ) ( 221,642 ) Loss before income taxes and noncontrolling interests ( 351,607 ) ( 413,645 ) ( 583,892 ) Income tax benefit 135 — 40 Net loss ( 351,472 ) ( 413,645 ) ( 583,852 ) Net loss attributable to noncontrolling interests, net of tax ( 74 ) ( 81 ) ( 656 ) Net loss attributable to ImmunityBio common stockholders $ ( 351,398 ) $ ( 413,564 ) $ ( 583,196 ) Net loss per ImmunityBio common share – basic $ ( 0.38 ) $ ( 0.59 ) $ ( 1.15 ) Net loss per ImmunityBio common share – diluted $ ( 0.38 ) $ ( 0.62 ) $ ( 1.15 ) Weighted-average number of common shares used in computing net loss per share – basic 919,863 697,312 508,636 Weighted-average number of common shares used in computing net loss per share – diluted 919,863 700,443 508,636 The accompanying notes are an integral part of these consolidated financial statements. 166 Table of Contents ImmunityBio, Inc. and Subsidiaries Consolidated Statements of Comprehensive Loss (in thousands) Year Ended December 31, 2025 2024 2023 Net loss $ ( 351,472 ) $ ( 413,645 ) $ ( 583,852 ) Other comprehensive income (loss), net of income taxes: Change in fair value of related-party convertible note related to instrument-specific credit risk 27,557 1,221 — Reclassification of net realized gains (losses) on available-for-sale securities included in net loss 292 42 ( 15 ) Net unrealized (losses) gains on available-for-sale securities ( 202 ) 15 60 Foreign currency translation adjustments 111 ( 90 ) ( 218 ) Total other comprehensive income (loss) 27,758 1,188 ( 173 ) Comprehensive loss ( 323,714 ) ( 412,457 ) ( 584,025 ) Less: Comprehensive loss attributable to noncontrolling interests 74 81 656 Comprehensive loss attributable to ImmunityBio common stockholders $ ( 323,640 ) $ ( 412,376 ) $ ( 583,369 ) The accompanying notes are an integral part of these consolidated financial statements. 167 Table of Contents ImmunityBio, Inc. and Subsidiaries Consolidated Statements of Stockholders’ Deficit (in thousands, except share amounts) Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total ImmunityBio Stockholders’ Deficit Noncontrolling Interests Total Stockholders’ Deficit Shares Amount Balance as of December 31, 2022 421,569,115 $ 42 $ 1,930,936 $ ( 2,378,488 ) $ 183 $ ( 447,327 ) $ ( 2,493 ) $ ( 449,820 ) Issuance of common stock “at-the market” offering, net of commissions and offering costs of $ 457 5,605,323 1 16,105 — — 16,106 — 16,106 Issuance of common stock in exchange for notes payable 209,291,936 21 269,966 — — 269,987 — 269,987 Issuance of shares in RDOs, net of discounts and offering costs of $ 3,535 and value ascribed to associated warrants 28,641,911 3 36,928 — — 36,931 — 36,931 Issuance of common stock in connection with the RIPA, net of transaction costs of $ 473 2,432,894 — 11,581 — — 11,581 — 11,581 Gain on debt extinguishment with related-parties under common control — — 36,110 — — 36,110 — 36,110 Increase in fair value of embedded conversion feature from debt modification with entities under common control — — 31,179 — — 31,179 — 31,179 Stock-based compensation expense — — 49,163 — — 49,163 — 49,163 Exercise of stock options 184,362 — 294 — — 294 — 294 Vesting of RSUs 4,545,644 — — — — — — — Net share settlement for RSUs vesting ( 1,403,841 ) — ( 3,443 ) — — ( 3,443 ) — ( 3,443 ) Change in ownership interest in a joint venture due to legal settlement — — ( 4,199 ) — — ( 4,199 ) 4,199 — Other comprehensive loss, net of tax — — — — ( 173 ) ( 173 ) — ( 173 ) Net loss — — — ( 583,196 ) — ( 583,196 ) ( 656 ) ( 583,852 ) Balance as of December 31, 2023 670,867,344 67 2,374,620 ( 2,961,684 ) 10 ( 586,987 ) 1,050 ( 585,937 ) The accompanying notes are an integral part of these consolidated financial statements. 168 Table of Contents ImmunityBio, Inc. and Subsidiaries Consolidated Statements of Stockholders’ Deficit (Continued) (in thousands, except share amounts) Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total ImmunityBio Stockholders’ Deficit Noncontrolling Interests Total Stockholders’ Deficit Shares Amount Issuance of common stock “at-the market” offering, net of commissions and offering costs of $ 660 427,368 — 3,625 — — 3,625 — 3,625 Conversion of related-party convertible notes and accrued interest into equity 117,185,260 11 188,526 — — 188,537 — 188,537 Issuance of shares in an equity offering, net of offering costs of $ 8,073 38,333,334 4 106,923 — — 106,927 — 106,927 Gain on debt extinguishment with related-parties under common control — — 10,418 — — 10,418 — 10,418 Stock-based compensation expense — — 34,432 — — 34,432 — 34,432 Exercise of stock options 308,959 — 715 — — 715 — 715 Vesting of RSUs 4,269,864 — — — — — — — Net share settlement for RSUs vesting ( 1,589,519 ) — ( 5,465 ) — — ( 5,465 ) — ( 5,465 ) Exercise of warrants 22,242,740 3 163,519 — — 163,522 — 163,522 Exercise of Oberland stock option, net of commissions of $ 150 858,990 — 7,554 — — 7,554 — 7,554 Other comprehensive income, net of tax — — — — 1,188 1,188 — 1,188 Net loss — — — ( 413,564 ) — ( 413,564 ) ( 81 ) ( 413,645 ) Balance as of December 31, 2024 852,904,340 85 2,884,867 ( 3,375,248 ) 1,198 ( 489,098 ) 969 ( 488,129 ) The accompanying notes are an integral part of these consolidated financial statements. 169 Table of Contents ImmunityBio, Inc. and Subsidiaries Consolidated Statements of Stockholders’ Deficit (Continued) (in thousands, except share amounts) Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total ImmunityBio Stockholders’ Deficit Noncontrolling Interests Total Stockholders’ Deficit Shares Amount Issuance of common stock “at-the market” offering, net of commissions and offering costs of $ 6,345 98,793,729 10 250,118 — — 250,128 — 250,128 Issuance of shares in equity offerings, net of offering costs of $ 2,693 and value ascribed to associated warrants 58,654,400 6 27,371 — — 27,377 — 27,377 Stock-based compensation expense — — 36,809 — — 36,809 — 36,809 Exercise of stock options 110,020 — 220 — — 220 — 220 Vesting of RSUs 2,153,485 — — — — — — — Net share settlement for RSUs vesting ( 815,966 ) — ( 2,265 ) — — ( 2,265 ) — ( 2,265 ) Other comprehensive income, net of tax — — — — 27,758 27,758 — 27,758 Net loss — — — ( 351,398 ) — ( 351,398 ) ( 74 ) ( 351,472 ) Balance as of December 31, 2025 1,011,800,008 $ 101 $ 3,197,120 $ ( 3,726,646 ) $ 28,956 $ ( 500,469 ) $ 895 $ ( 499,574 ) The accompanying notes are an integral part of these consolidated financial statements. 170 Table of Contents ImmunityBio, Inc. and Subsidiaries Consolidated Statements of Cash Flows (in thousands) Year Ended December 31, 2025 2024 2023 Operating activities: Net loss $ ( 351,472 ) $ ( 413,645 ) $ ( 583,852 ) Adjustments to reconcile net loss to net cash used in operating activities: Change in fair value of warrant liabilities ( 49,089 ) ( 19,955 ) 47,600 Change in fair value of related-party convertible note 42,773 ( 43,472 ) 36,203 Non-cash interest expense related to revenue interest liability 41,229 38,004 264 Stock-based compensation expense 36,809 34,432 49,163 Depreciation and amortization 15,525 17,554 18,512 Loss due to write-off of fixed assets 14,018 — — Change in fair value of derivative liabilities ( 6,398 ) ( 13,477 ) — Non-cash lease expense related to operating lease right-of-use assets 3,502 3,309 3,113 Non-cash lease expense related to operating lease right-of-use assets – related parties 2,754 2,447 2,999 Accretion of discounts on marketable debt securities, available-for-sale ( 2,745 ) ( 1,489 ) ( 137 ) Transaction costs allocated to warrant liabilities 2,167 — 2,010 Non-cash interest items, net ( 250 ) 1,150 8,925 Amortization of related-party notes discounts — 22,587 42,396 Unrealized losses on equity securities — 632 1,591 Impairment of intangible assets — — 886 Other 570 109 ( 258 ) Changes in operating assets and liabilities: Accounts receivable ( 40,211 ) ( 2,360 ) — Inventories ( 6,325 ) ( 8,272 ) — Prepaid expenses and other current assets ( 7,068 ) 3,681 4,925 Prepaid expenses – related parties 2,211 ( 1,978 ) 1,033 Other assets 803 ( 1,108 ) 1,764 Accounts payable ( 190 ) ( 3,167 ) ( 6,476 ) Accrued expenses and other liabilities 3,184 ( 1,508 ) 6,689 Due to and due from related parties, net 477 763 ( 1,129 ) Operating lease liabilities ( 3,749 ) ( 2,473 ) ( 1,228 ) Operating lease liabilities – related parties ( 3,461 ) ( 3,000 ) ( 1,750 ) Net cash used in operating activities ( 304,936 ) ( 391,236 ) ( 366,757 ) Investing activities: Purchases of marketable debt securities, available-for-sale ( 241,373 ) ( 140,218 ) ( 10,358 ) Proceeds from maturities of marketable debt securities, available-for-sale 64,897 115,586 10,100 Proceeds from sales of marketable debt securities, available-for-sale 30,927 21,021 372 Purchases of property, plant and equipment ( 3,846 ) ( 6,888 ) ( 30,584 ) Software development costs ( 406 ) — — Acquisition of a business, net of transaction costs — ( 1,000 ) — Cash paid for other investments — ( 747 ) — Net cash used in investing activities ( 149,801 ) ( 12,246 ) ( 30,470 ) The accompanying notes are an integral part of these consolidated financial statements. 171 Table of Contents ImmunityBio, Inc. and Subsidiaries Consolidated Statements of Cash Flows (Continued) (in thousands) Year Ended December 31, 2025 2024 2023 Financing activities: Proceeds from equity offerings, net of discounts and issuance costs $ 400,562 $ 111,357 $ 100,561 Proceeds from short-term borrowings 2,884 — — Net share settlement for RSUs vesting ( 2,265 ) ( 5,465 ) ( 3,443 ) Principal payments on premium financing ( 1,132 ) — — Proceeds from exercises of stock options 220 715 294 Principal payments of finance leases ( 28 ) ( 64 ) ( 77 ) Proceeds from the RIPA, net of issuance costs — 96,956 192,764 Proceeds from exercises of warrants — 73,281 — Proceeds from exercise of Oberland stock option, net of commissions — 4,850 — Proceeds from issuance of related-party promissory notes, net of issuance costs paid — — 258,700 Proceeds from stock option issuance in connection with the RIPA, net of transaction costs — — 9,542 Net cash provided by financing activities 400,241 281,630 558,341 Effect of exchange rate changes on cash and cash equivalents, and restricted cash 15 ( 23 ) ( 292 ) Net change in cash and cash equivalents, and restricted cash ( 54,481 ) ( 121,875 ) 160,822 Cash and cash equivalents, and restricted cash, beginning of year 143,912 265,787 104,965 Cash and cash equivalents, and restricted cash, end of year $ 89,431 $ 143,912 $ 265,787 The accompanying notes are an integral part of these consolidated financial statements. 172 Table of Contents ImmunityBio, Inc. and Subsidiaries Consolidated Statements of Cash Flows (Continued) (in thousands) Year Ended December 31, 2025 2024 2023 Reconciliation of cash, cash equivalents, and restricted cash, end of year: Cash and cash equivalents $ 88,334 $ 143,428 $ 265,453 Restricted cash ( Note 2 ) 1,097 484 334 Cash, cash equivalents, and restricted cash, end of year $ 89,431 $ 143,912 $ 265,787 Supplemental disclosure of cash flow information: Cash paid during the year for: Interest $ 71,321 $ 92,318 $ 77,192 Income taxes — 15 8 Non-cash investing and financing activities: Initial measurement of warrants issued in connection with equity offerings accounted for as liabilities $ 124,931 $ — $ 49,534 Issuance of common stock upon vesting of RSUs 5,915 14,623 10,456 Right-of-use assets obtained in exchange for operating lease liabilities 5,903 2,576 — Property and equipment purchases included in accounts payable, accrued expenses and other liabilities, and due to related parties 1,355 748 1,156 Right-of-use assets obtained in exchange for finance lease liabilities 307 — — Unpaid offering costs included in accounts payable, and accrued expenses and other liabilities 293 805 255 Conversion of related-party convertible notes and accrued interest, net of unamortized discount, into equity — 188,537 269,987 Gain on extinguishment of debt with related parties under common control — 10,418 36,110 Increase in fair value of embedded conversion feature from debt modification — — 31,179 Change in ownership interest in a joint venture due to legal settlement — — 4,199 Right-of-use assets disposed in exchange for operating lease liabilities — — ( 3,777 ) Common stock issuance discount related to revenue interest liability — — 2,039 The accompanying notes are an integral part of these consolidated financial statements. 173 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements 1. Description of Business In these notes to the consolidated financial statements, the terms “ImmunityBio,” “the company,” “we,” “us,” and “our” refer to ImmunityBio and its subsidiaries. Our Business ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 superagonist, ANKTIVA (nogapendekin alfa inbakicept). Our Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy. 2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements have been prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of the SEC. The consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. Certain items in prior years’ consolidated financial statements have been reclassified to conform to the current presentation. These reclassifications had no effect on the reported results of operations. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the company and its wholly-owned subsidiaries, and one non wholly-owned subsidiary. All intercompany transactions and balances have been eliminated upon consolidation. For consolidated entities in which we have less than 100% ownership, we record net loss attributable to noncontrolling interests, net of tax, on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. Liquidity As of December 31, 2025, the company had an accumulated deficit of $ 3.7 billion. We also had negative cash flows from operations of $ 304.9 million during the year ended December 31, 2025. The company will need to obtain additional financing to fund our future operations, including the commercialization of our approved product and the development and commercialization of our other product candidates. The consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. 174 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) We expect to take some time to generate sufficient revenue from our approved product to offset expenses. We may also seek to sell additional equity through one or more follow-on offerings, or in separate financings, or obtain incremental subordinated debt in compliance with our existing revenue interest liability. However, we may not be able to secure such external financing in a timely manner or on favorable terms. Without significant sales of our approved product or additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the global commercialization of our approved product and our other product candidates, we may need additional funds to meet our needs sooner than planned. As a result of continuing anticipated operating cash outflows as we commercialize our approved product and accelerate our development efforts, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash and cash equivalents, and investments in marketable securities; sales of our approved product; capital to be raised through equity offerings; and our potential ability to borrow from affiliated entities will be sufficient to fund our operations through at least the next 12 months following the issuance date of the consolidated financial statements based primarily upon our Founder, Executive Chairman and Global Chief Scientific and Medical Officer’s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. Revenue Product Sales and Sales Deductions The company recognizes product revenue from product sales when obligations under the terms of a contract with a customer are satisfied. This occurs upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. The company’s customers are currently limited to pharmaceutical specialty distributors and a specialty pharmacy as the company currently operates under a third-party logistics agreement to engage a 3PL Agent to distribute the company’s products to its customers. Product revenue is recorded with each sale at wholesale acquisition cost, net of: (a) consideration payable to customers; and (b) variable consideration. The company pays fees to the specialty distributors and specialty pharmacy for certain administrative services associated with the distribution of the product. Such fees are not for a distinct good or service and, accordingly, are recorded as a reduction of revenue, as well as a reduction of accounts receivable (trade discounts) or as a component of accrued expenses (distributor fees). The variable consideration components include, but are not limited to, prompt payment discounts, product returns, chargebacks, rebates, and co-payment assistance, which are collectively referred to as “gross-to-net adjustments.” In accordance with ASC 606, the company must make judgments to determine the estimates for certain variable considerations. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable consideration components. Where appropriate, these estimates are based on factors such as industry and forecasted customer buying and payment patterns, our experience, current contractual and statutory requirements, and specific known market events and trends. Variable consideration is reassessed each reporting period, and adjustments are recorded on a cumulative catch-up basis, which affects product revenue and net income in the period of adjustment. The actual amounts of variable consideration ultimately received may differ from our estimates. If actual results in future periods vary from our estimates, we adjust these estimates accordingly. 175 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Other Revenues Prior to the approval of ANKTIVA for commercial sale, we primarily generated revenues from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables, and grant programs. The company expects to continue to generate revenue from these programs. We sell our proprietary GMP-in-a-Box bioreactors and related consumables to affiliated companies and third parties. The arrangements typically include delivery of bioreactors, consumables, and providing installation service, extended warranty service, and perpetual software licenses for using the equipment. We recognize revenue when customers obtain control and can benefit from the promised goods or services, generally upon installation of the bioreactors, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. Upfront payments and fees are recorded as deferred revenue upon receipt and recognized as revenue when we satisfy our performance obligations under these arrangements. The company also has nonexclusive license agreements with a limited number of pharmaceutical and biotechnology companies that grant them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines. Under our license agreements with customers, we typically promise to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent a single performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. Research and development data are provided throughout the term of the contract when and if available. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied. Our license agreements may include non-refundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration, and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainty around the achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded prospectively as a cumulative adjustment to revenue recognized in the current period. Research and Development Costs Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials costs, including CROs and related clinical manufacturing, including third-party CMOs, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred. The company classifies its research and development expenses as either external or internal. The company’s external research and development expenses support its various preclinical and clinical programs. The company’s internal research and development expenses include payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of its research and development activities. The company’s external and internal resources are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs and are not allocated to specific product candidates or development programs. 176 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the preclinical studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates. We adjust the accruals in the period when actual costs become known. Cost of Sales Cost of sales consists primarily of third-party manufacturing costs, distribution, and overhead costs related to sales of approved product subsequent to receiving regulatory approval. Cost of sales may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. All costs associated with the production of ANKTIVA prior to receiving regulatory approval were expensed in research and development expense , on the consolidated statement of operations in the period incurred and therefore are not reflected in cost of sales. Accounts Receivable, Net Accounts receivable is recorded net of allowances for prompt payment discounts, product returns, chargebacks, distributor fees, and credit losses. The company estimates an allowance for credit losses by considering factors such as credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. As of December 31, 2025, the credit profile for the company’s counterparties was deemed to be in good standing, and as such an allowance for credit losses was not recorded. Inventories Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. The company classifies inventory as long-term when a sale of the inventory is expected beyond 12 months. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. Inventory reserves are established based on the analysis of inventory levels for excess quantities and obsolescence, considering factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf life. See Note 4 “ Inventories” for more information. Contingencies The company records accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred, and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability previously recorded or the range of potential losses disclosed. Concentration of Major Customers The company relies heavily on a limited number of customers to market and distribute ANKTIVA to various healthcare institutions or end users. During the year ended December 31, 2025, approximately 96 % of our total gross revenue was from our top four customers, which accounted for 42 %, 19 %, 18 % and 17 % of our total revenue, respectively. As of December 31, 2025, our trade accounts receivable, net are mainly from sales of ANKTIVA. 177 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Our dependency on a few key customers exposes us to several risks, including the potential for disruptions in our distribution network, changes in customers’ business strategies, or financial difficulties faced by these customers. Any significant disruption or change in our relationship with these customers could materially and adversely affect our ability to effectively reach other potential end users and maintain our market position. Additionally, we maintain regular communication and strong relationships with our existing customers to ensure alignment with our business objectives. While we believe our relationships with these customers are strong and mutually beneficial, there can be no assurance that we will be able to maintain these relationships or that we will be able to replace them with new specialty distributors if necessary. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject us to concentration of risk consist principally of cash and cash equivalents, marketable securities, trade accounts receivable and a convertible note receivable. We attempt to minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. Our investment portfolio is maintained in accordance with our investment policy. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts. The company is also subject to credit risk related to its trade accounts receivable from product sales. ANKTIVA is distributed primarily through specialty distributors and a specialty pharmacy. The company is operating under a title model with its 3PL Agent and the 3PL Agent retains all credit and collection risk on sales to the company’s specialty distributors and specialty pharmacy. As of December 31, 2025, the company’s 3PL Agent made up 100 % of its trade accounts receivable, net balance. Historically, the company has not experienced any credit losses from product sales. We also monitor the creditworthiness of the borrower of the convertible note receivable. We believe that any concentration of credit risk in its convertible note receivable was mitigated in part by our ability to convert, if necessary, at the qualifying financing event or upon a payment default into shares of the senior class of equity securities of the borrower. Our product and product candidates will require incremental approvals or clearances from the FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product or product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us. Cash, Cash Equivalents, and Restricted Cash Cash equivalents include highly liquid investments with an original maturity of three months or less from the date of purchase. Restricted cash includes multiple bank accounts being held as collateral, which are pledged for the company’s credit card program, as well as a substitute letter of credit for certain of our leased properties. The landlords are the beneficiaries of the cash collateral account related to certain of our leased properties, and we are unable to access the funds during the terms of the leases. Restricted cash is included in other assets, on the consolidated balance sheet. 178 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Marketable Securities and Other Investments Marketable Debt Securities The company holds investments in marketable debt securities consist mainly of government-sponsored securities. Marketable debt securities with remaining maturities greater than three months when acquired are classified as available-for-sale. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets. Marketable debt securities with remaining maturities of 12 months or less are classified as short-term and marketable securities with remaining maturities greater than 12 months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of accumulated other comprehensive income, on the consolidated statement of stockholders’ deficit, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in interest and investment income (loss), net , on the consolidated statement of operations. Realized gains and losses from sales of securities and the amounts, net of tax, reclassified out of accumulated other comprehensive income , if any, are determined on a specific identification basis. Marketable Equity Securities Investments in mutual funds and equity securities, other than equity method investments, are recorded at fair market value, if fair value is readily determinable and any unrealized gains and losses are included in other income (expense), net, on the consolidated statement of operations. Realized gains and losses from the sale of the securities are determined on a specific identification basis and the amounts are included in other income (expense), net, on the consolidated statement of operations. Evaluating Investments for Other-than-Temporary Impairments We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether we have plans to sell the security or whether it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. Our other-than-temporary impairments are further discussed in Note 8 “ Financial Instruments .” Equity Method of Accounting In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity. In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the investee and other relevant factors such as the presence of a collaborative or other business relationship. Under the equity method of accounting, we record our share of the income or loss of the investee, if any, in loss on equity method investment , on the consolidated statement of operations. Property, Plant and Equipment, Net Property, plant and equipment are stated at historical cost less accumulated depreciation and, if applicable, impairment charges. We review our property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. All repairs and maintenance are charged to operating expenses during the financial period in which they are incurred. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated lives or lease terms. See Note 5 “Property, Plant and Equipment, Net” for information regarding the estimated useful lives of our assets. Upon disposal of property, plant and equipment, the cost and related accumulated depreciation are removed from the consolidated financial statements and the net amount, less any proceeds, is included in other income (expense), net , on the consolidated statement of operations. 179 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Intangible Assets, Net Intangible assets acquired in a business combination are initially recognized at their fair value on the acquisition date. Acquired indefinite-lived assets, such as IPR&D acquired in a business combination, are not amortized until they become definite-lived assets, upon the successful completion of the associated research and development effort. At that time, we determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned, the related IPR&D assets are written-off and an impairment charge recorded. IPR&D acquired in an asset acquisition is expensed immediately. Acquired definite-lived intangible assets are amortized using the straight-line method over their respective estimated useful lives. The amortization of these intangible assets is included in selling, general and administrative expense, on the consolidated statement of operations. Impairment of Long-lived and Indefinite-lived Assets The company accounts for the impairment and disposition of long-lived assets in accordance with FASB ASC Topic 360, Property, Plant, and Equipment . The company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. If so, the company makes an assessment of recoverability of the net carrying value of the asset group in which the long-lived asset resides over the remaining useful life of the primary asset in the asset group. The asset group is determined based on the lowest level for which identifiable cash flows can be identified. If this assessment indicates that the long-lived asset group is not recoverable, based on the estimated undiscounted future cash flows of the asset group, the company reduces the net carrying value of the related long-lived assets in the asset group to fair value and may adjust the remaining amortization period. The company accounts for the impairment and disposition of indefinite-lived intangible assets in accordance with FASB ASC Topic 350, Intangibles—Goodwill and Other . The company evaluates qualitative factors for impairment at least annually or more frequently whenever events or changes in circumstances indicate that the assets are impaired. If after the qualitative testing, it is more likely than not that the assets are impaired, then the company shall calculate the fair value of the assets and perform the quantitative impairment test by comparing the fair value of the assets with their carrying values. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying values of the assets exceed their fair value. Asset Acquisitions and Business Combinations We make certain judgments to determine whether transactions should be accounted for as acquisitions of assets or as business combinations. If it is determined that substantially all of the fair value of gross assets acquired in a transaction is concentrated in a single asset (or a group of similar assets), the transaction is treated as an acquisition of assets. We evaluate the inputs, processes, and outputs associated with the acquired set of activities and assets. If the assets in a transaction include an input and a substantive process that together significantly contribute to the ability to create outputs, the transaction is treated as an acquisition of a business. In transactions accounted for as asset acquisitions, the cost of an asset acquisition, including transaction costs, are allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. In an asset acquisition, upfront payments allocated to in-process research and development projects at the acquisition date are expensed unless there is an alternative future use. In addition, product development milestones are expensed upon achievement. Any contingent consideration, such as payments upon achievement of various developmental, regulatory, and commercial milestones, generally is not recognized at the acquisition date. Business combinations are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed generally be recorded at their fair values as of the acquisition date. Excess of consideration over the fair value of net assets acquired is recorded as goodwill. Estimating fair value requires us to make significant judgments and assumptions. Acquisition costs related to a business combination are expensed as incurred. 180 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Contingent consideration incurred in connection with a business combination is recorded at fair values on the acquisition date and re-measured at its revised fair value each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair value are recorded in operating expenses on the consolidated statements of operations and comprehensive loss. Changes in fair value reflect changes to our assumptions regarding probabilities of successful achievement of related milestones, the timing in which the milestones are expected to be achieved, and the discount rate used to estimate the fair value of the obligation. Common Control Transactions Transactions between us and entities where Dr. Soon-Shiong and his affiliates are the controlling stockholders are accounted for as common control transactions whereby the net assets acquired or transferred are accounted at their carrying value. Any difference between the carrying value and consideration recognized is treated as a capital transaction. Cash consideration up to the carrying value of the net assets acquired or transferred is presented as an investing activity on the consolidated statement of cash flows. Cash consideration in excess of the carrying value of the net assets acquired or transferred is presented as a financing activity on the consolidated statement of cash flows. Cloud Computing Arrangement The company capitalizes implementation costs under a cloud computing arrangement that is a service contract in line with its policy for internal-use software. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included in prepaid expenses and other current assets and other assets, on the consolidated balance sheet. Amortization of capitalized implementation costs is recognized on a straight-line basis over the shorter of the estimated useful life or the terms of the underlying hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred. Fair Value Measurements Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: • Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of bank deposits, treasuries, money market funds, and marketable equity securities. • Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. • Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement. We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations. During the years ended December 31, 2025, 2024 and 2023, no transfers were made into or out of the Level 1, 2 or 3 categories. We will continue to review the fair value inputs on a quarterly basis. See Note 9 “Fair Value Measurements” for more information. 181 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Collaboration Arrangements We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808. A collaborative arrangement is a contractual arrangement that involves joint operating activity. These arrangements involve two or more parties who are active participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activity. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. To the extent the collaboration agreement is within the scope of ASC 808, we also assess whether the arrangement contains multiple elements that are within the scope of other accounting literature. If we conclude that some or all aspects of the agreement are distinct and represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606. Amounts that are owed by collaboration partners within the scope of ASC 808 are recognized as an offset to research and development expense as such amounts are incurred by the collaboration partner. The amounts owed to a collaboration partner are classified as research and development expense. Our collaboration arrangements require us to acquire certain equipment for exclusive use in the joint operating activities. These equipment purchases do not have an alternative use and are therefore expensed as incurred within research and development expense. Our collaboration arrangements are further discussed in Note 10 “Collaboration and License Agreements and Acquisition.” Transactions with Related Parties As outlined in Note 14 “Related-Party Debt” and Note 15 “Related-Party Agreements,” we have various agreements with related parties. These arrangements can be billed and settled in cash monthly, billed quarterly and settled in cash the following month, or estimated in advance and collected or paid upfront based on expected utilization. Monthly accruals are made for all quarterly billing arrangements. Leases The company determines whether an arrangement contains a lease at the inception of the contract and classify each lease as a finance lease or an operating lease. For all leases other than short-term leases, the company recognizes right-of-use assets and a lease liabilities at commencement date. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The lease liability is measured as the present value of the lease payments over the lease term. When determining the present value of lease payments, the company uses incremental borrowing rate on the date of lease commencement, or the rate implicit in the lease, if known. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of operating right-of-use-assets and leasehold improvements is determined by the expected lease term. For finance leases, the right-of-use asset is amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the right-of-use asset is amortized over the useful life of the underlying asset. The company elected not to recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of one year or less. The lease term includes the non-cancellable period of the lease. The company does not assume renewal options in our lease term assessment unless the company is reasonably certain at lease inception. Any assumptions that the company made at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. 182 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The company elected to account for lease and non-lease components together as a single lease component for all underlying assets. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes. Warrants The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the company’s own stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For warrants that meet all criteria for equity classification, the warrants are required to be recorded at their initial fair value at the time of issuance, as a component of additional paid-in capital, on the consolidated statement of stockholders’ deficit. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recorded as a non-cash gain or loss in other income (expense), net , on the consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model. Related-Party Convertible Note at Fair Value The company elected to apply the FVO method of accounting in accordance with ASC 825 and accounts for certain of its notes and embedded derivatives at fair value as a single instrument in accordance with ASC 815. The notes for which the FVO is elected are recorded at fair value upon the date of issuance and subsequently remeasured to fair value at each reporting period. Changes in the fair value of the notes accounted for at fair value are recorded as a component of other income (expense), net , on the consolidated statement of operations, except that changes in fair value caused by instrument-specific credit risk are recorded separately in other comprehensive income (loss), on the consolidated statement of comprehensive loss. The cumulative amount previously recorded in other comprehensive income (loss) resulting from changes in the instrument-specific credit risk for extinguished notes are reclassified and reported in current earnings on the consolidated statement of operations. All costs associated with the issuance of the convertible promissory note accounted for using the FVO were expensed upon issuance. The company applied the FVO to the $ 505 million December 2024 Promissory Note and $ 30 million March 2023 Promissory Note prior to its extinguishment on December 29, 2023. See Note 14 “Related-Party Debt” for more information. Debt Modification and Extinguishment The company evaluates amendments to its debt instruments in accordance with ASC 470-50. This evaluation includes comparing (1) if applicable, the net present value of future cash flows of the amended debt to that of the original debt and (2) the change in fair value of an embedded conversion feature to that of the carrying amount of the debt immediately prior to amendment to determine, in each case, if a change greater than 10% occurred. In instances where the net present value of future cash flows or the fair value of an embedded conversion feature, if any, changed more than 10%, the company applies extinguishment accounting. In instances where the net present value of future cash flows and the fair value of an embedded conversion feature, if any, changed less than 10%, the company accounts for the amendment to the debt as a debt modification. Gains and losses on debt amendments that are considered extinguishments are recognized in current earnings or in additional paid-in capital if the transactions are with entities under common control. Debt amendments that are considered debt modifications are accounted for prospectively through yield adjustments, based on the revised terms. Legal fees and other costs incurred with third parties that are directly related to debt modifications are expensed as incurred. Amounts paid by the company to the lenders, are reflected as additional debt discount and amortized as an adjustment of interest expense over remaining term of modified debt using the effective interest rate method. 183 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Income Taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce deferred tax assets to the amount we believe is more likely than not to be realized. We recognize uncertain tax positions when the position will more likely than not be upheld on examination by the taxing authorities based solely upon the technical merits of the positions. We recognize interest and penalties, if any, related to unrecognized income tax uncertainties in income tax benefit (expense), on the consolidated statement of operations. We did not have any accrued interest or penalties associated with uncertain tax positions as of December 31, 2025 and 2024. Revenue Interest Liability On December 29, 2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain Revenue Interests (as defined in the RIPA) from us for a gross purchase price of $ 200.0 million paid on closing and acquired additional Revenue Interests from us for a gross purchase price of $ 100.0 million paid on May 13, 2024. Under the RIPA, Oberland has the right to receive quarterly payments from us based on, among other things, a certain percentage of our worldwide net sales, excluding those in China, during such quarter. The RIPA is considered a sale of future revenues and is accounted for as a liability net of a debt discount comprised of deferred issuance costs, the fair value of a freestanding option agreement related to the SPOA, and the fair value of embedded derivatives requiring bifurcation on the consolidated balance sheet. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the consolidated statement of operations. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales. The company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. Derivatives Embedded derivatives that are required to be bifurcated from the underlying debt instrument that do not meet the derivative scope exception and equity classification criteria are accounted for and valued as separate financial instruments. During the year ended December 31, 2024, the terms of an embedded derivative related to a contingent exercisable prepayment feature of a related-party convertible note (the $ 505 million December 2023 Promissory Note) required bifurcation. This embedded derivative was initially measured at fair value and was remeasured to fair value at each reporting date until the derivative would be settled. On December 10, 2024, the company and Nant Capital entered into a second amended and restated promissory note (the $ 505 million December 2024 Promissory Note) for which the FVO method of accounting was elected. As such, the bifurcation of the embedded derivative was no longer required. The embedded derivative is now included within the fair value of the second amended and restated promissory note recorded within related-party convertible note payable at fair value , on the consolidated balance sheet. In addition, the RIPA contains certain features that meet the definition of being an embedded derivative requiring bifurcation as a separate compound financial instrument apart from the RIPA. The derivative liability is initially measured at fair value upon issuance and is subject to remeasurement at each reporting period with changes in fair value recognized in other income (expense), net , on the consolidated statement of operations. 184 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Stock-Based Compensation The company accounts for stock-based compensation under the provisions of ASC 718. Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date and recognized over the requisite service period. We estimate fair value of each stock option award on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of subjective assumptions, including, but not limited to, expected stock price volatility over the term of the awards and the expected term of the stock options. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited. See Note 18 “Stock-Based Compensation” for more information. Comprehensive Loss Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income or loss is composed of net (loss) income and other comprehensive (loss) income. Our other comprehensive income or loss consists of net unrealized gains (losses) on marketable debt securities classified as available-for-sale, the change in fair value of convertible note resulting from a change in the instrument-specific credit risk, net of income taxes and foreign currency translation adjustments. Noncontrolling Interests Noncontrolling interests are recorded for the entities that we consolidate but are not wholly-owned by the company. Noncontrolling interests are classified as a separate component of equity on the consolidated balance sheet and consolidated statement of stockholders’ deficit. Additionally, net loss attributable to noncontrolling interests is reflected separately from consolidated net loss on the consolidated statement of operations and the consolidated statement of stockholders’ deficit. We record the noncontrolling interests’ share of loss based on the percentage of ownership interest retained by the respective noncontrolling interest holders. Noncontrolling interests recorded on the consolidated financial statements result from the company’s share of GlobeImmune, of which we controlled 69.1 % as of December 31, 2025 and 2024, respectively. Noncontrolling interest stockholders are common stockholders. Foreign Currencies We have operations and hold assets in Italy. The functional currency of the subsidiary in Italy is the Euro, based on the nature of the transactions occurring within this entity, and accordingly, assets and liabilities of this subsidiary is translated into U.S. dollars at exchange rates prevailing as of the balance sheet dates, while the operating results are translated into U.S. dollars using the average exchange rates for the period correlating with those operating results. In 2025, we also formed a wholly-owned subsidiary in Ireland. However, the subsidiary in Ireland did not have any transactions during year ended December 31, 2025. Adjustments resulting from translating the financial statements of the foreign subsidiary into U.S. dollars are recorded as a component of other comprehensive (loss) income , on the consolidated statement of comprehensive loss. Transaction gains and losses are recorded in other income (expense), net, on the consolidated statement of operations. 185 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Recent Accounting Pronouncements Application of New or Revised Accounting Standards – Adopted In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , to improve its income tax disclosure requirements. Under this ASU, entities must annually (1) disclose specific categories in the rate reconciliation, (2) provide additional information for reconciling items that meet a quantitative threshold, and (3) disclose more detailed information about income taxes paid, including by jurisdiction; pretax income (or loss) from continuing operations; and income tax expense (or benefit). This ASU was effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We adopted this ASU on December 31, 2025 on a prospective basis. See Note 19 “Income Taxes” for more information. Application of New or Revised Accounting Standards – Not Yet Adopted In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses , which requires that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU 2025-01 to clarify the effective date. All public business entities should initially adopt the disclosure requirements in the first annual reporting period beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. This ASU may be applied either on a prospective or retrospective basis. We are currently evaluating the impact of this standard on our disclosures. In November 2024, the FASB issued ASU 2024-04, Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments , which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. This ASU is effective for fiscal years beginning after December 15, 2025 and interim reporting periods within those annual reporting periods, with early adoption permitted. We do not expect this ASU to have a material impact on our consolidated financial statements. In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets , which provides a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC 606. The practical expedient permits an entity to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets. The ASU is effective for fiscal years beginning after December 15, 2025 and interim reporting periods within those annual reporting periods, with early adoption permitted. We are currently evaluating the impact of this standard and do not expect the adoption to have a material impact on our consolidated financial statements. We expect to apply the practical expedient for qualifying current receivables and contract assets upon adoption. In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software , which clarifies and modernizes the accounting for costs related to internal-use software. The amendments in ASU 2025-06 remove all references to project stages and clarify the threshold entities apply to begin capitalizing costs. The ASU is effective for fiscal years beginning after December 15, 2027 and interim reporting periods within those annual reporting periods, with early adoption permitted. We are currently evaluating the impact of this standard on our consolidated financial statements. Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC) and the SEC during the year ended December 31, 2025 did not, or are not expected to, have a material effect on our consolidated financial statements. 186 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) 3. Revenues As discussed in Note 2 “Summary of Significant Accounting Policies , ” revenues are recognized in accordance with ASC 606. The following table presents our disaggregated revenue for the periods presented (in thousands): Year Ended December 31, 2025 2024 2023 Product revenue, net $ 112,982 $ 14,150 $ — Other revenues 306 595 622 Total revenue $ 113,288 $ 14,745 $ 622 Product Revenue, Net During the years ended December 31, 2025 and 2024, our product revenue has been from U.S. sales of ANKTIVA, which we began shipping to customers in May 2024. During the years ended December 31, 2025 and 2024, approximately $ 21.1 million and $ 1.6 million of gross-to-net adjustments have been recorded as a reduction of revenue on the consolidated statements of operations, respectively . As of December 31, 2025 and 2024, approximately $ 2.0 million and $ 0.2 million of allowances for prompt payment discounts, product returns and chargebacks were included in accounts receivable, net, and approximately $ 6.3 million and $ 0.5 million related to accrued rebates, co-payment assistance and other fees were included in accrued expenses and other current liabilities, on the consolidated balance sheets, respectively. 4. Inventories Inventories consist of the following (in thousands): As of December 31, 2025 2024 Work-in-progress $ 12,524 $ 7,505 Finished goods 1,894 767 Inventories $ 14,418 $ 8,272 As of December 31, 2025, the company had $ 1.1 million of inventory on hand that was acquired prior to regulatory approvals. This inventory was expensed in research and development expense , on the consolidated statement of operation, as the future economic benefit was not probable. We began capitalizing inventory costs associated with ANKTIVA after receiving FDA approval in April 2024 when it was determined that the inventory had a probable future economic benefit. Inventory that is used for clinical development purposes is expensed in research and development expense , on the consolidated statement of operations when consumed. The company’s long-term inventories consist of work-in-process and finished goods that are expected to be sold beyond 12 months. As of December 31, 2025, the allowance for inventory reserve was $ 0.2 million. As of December 31, 2024, no allowance for inventory reserve was recorded. 187 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) 5. Property, Plant and Equipment, Net Property, Plant and Equipment, Net Property, plant and equipment, net, consist of the following (in thousands): Useful Life (in years) As of December 31, 2025 2024 Leasehold improvements (1) $ 73,141 $ 73,126 Equipment 3 to 7 years 63,259 73,578 Construction in progress 86,433 86,417 Furniture & fixtures 5 years 1,867 1,865 Software 3 years 2,049 1,697 Gross property, plant and equipment 226,749 236,683 Less: Accumulated depreciation 112,485 99,589 Property, plant and equipment, net $ 114,264 $ 137,094 _______________ (1) The useful life of leasehold improvements is the shorter of the lease term or life of the asset. During the years ended December 31, 2025, 2024 and 2023, depreciation expense related to property, plant and equipment totaled $ 13.4 million, $ 15.5 million and $ 16.5 million, respectively. 6. Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net Intangible assets, net and goodwill are as follows (in thousands): December 31, 2025 Weighted- Average Life Remaining (in years) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Definite-lived: Favorable leasehold rights 3.0 $ 20,398 $ ( 7,905 ) $ 12,493 Developed technology 4.5 553 ( 55 ) 498 Total definite-lived assets 20,951 ( 7,960 ) 12,991 Indefinite-lived: Goodwill 910 — 910 In-process software development 52 — 52 Total indefinite-lived assets 962 — 962 Goodwill and intangible assets, net $ 21,913 $ ( 7,960 ) $ 13,953 188 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) December 31, 2024 Weighted- Average Life Remaining (in years) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Definite-lived: Favorable leasehold rights 7.1 $ 20,398 $ ( 5,864 ) $ 14,534 Indefinite-lived: Goodwill 910 — 910 IPR&D 489 — 489 Total indefinite-lived assets 1,399 — 1,399 Goodwill and intangible assets, net $ 21,797 $ ( 5,864 ) $ 15,933 Definite-Lived Intangible Assets Favorable leasehold rights In connection with the acquisition of the Dunkirk Facility in 2022, we acquired definite-lived intangibles consisting of favorable leasehold rights. We recorded amortization expense of our favorable leasehold rights totaling $ 2.0 million during the years ended December 31, 2025, 2024 and 2023, respectively, in research and development expense , on the consolidated statements of operations. Developed technology In connection with the acquisition of VBC in 2015, we acquired IPR&D that was initially recognized at fair value on the acquisition date. As of September 30, 2025, the R&D efforts were deemed complete and we assigned an estimated useful life of five years to the developed technology. During the year ended December 31, 2025, we recorded $ 0.1 million of amortization expense for developed technology in research and development expense , on the consolidated statement of operations. Indefinite-Lived Intangible Assets Goodwill In September 2024, we entered into an asset purchase agreement with an unrelated party pursuant to which the company acquired the rights to hire its workforce and purchase certain office equipment in exchange for consideration of $ 1.0 million, net of transaction costs. The transaction was accounted for as a business combination. The fair value of the acquired identifiable net assets was $ 0.1 million. We recognized the remaining $ 0.9 million as goodwill. No goodwill impairment was recognized during the years ended December 31, 2025 and 2024. IPR&D During the year ended December 31, 2023, we discontinued the research and development program associated with the Tarmogen platform based on results gathered from clinical data. We recorded a charge totaling $ 0.9 million in impairment of intangible assets , on the consolidated statement of operations in connection with the write down of the carrying value of Tarmogen to zero. No such impairments were recorded during the years ended December 31, 2025 and 2024. As of December 31, 2025 and 2024, the company had an immaterial amount and $ 0.5 million of indefinite-lived IPR&D intangible assets, respectively. 189 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Future amortization expense associated with our definite-lived intangible assets, net is as follows (in thousands): Years ending December 31: Definite-lived Intangible Assets 2026 $ 4,275 2027 4,275 2028 4,275 2029 111 2030 55 Thereafter — Total $ 12,991 7. Financial Statements Details Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets (including related-party amounts) consist of the following (in thousands): As of December 31, 2025 2024 Prepaid research and development costs $ 9,542 $ 5,815 Prepaid services 7,072 7,762 Prepaid software license fees 3,594 2,687 Prepaid insurance 1,825 2,057 Insurance premium financing asset 1,751 1,248 Prepaid rent 1,474 1,532 Prepaid equipment maintenance 1,137 1,448 Other 2,135 1,303 Prepaid expenses and other current assets (including amounts with related parties) $ 28,530 $ 23,852 Convertible Note Receivable In 2016, we executed a convertible promissory note pursuant to which we advanced Riptide a principal amount of $ 5.0 million. The note bears interest at a per annum rate of 5 %. Concurrent with the transaction, we entered into an exclusive license agreement with Riptide to obtain worldwide exclusive rights, with the right to sublicense, certain know-how related to RP-182, RP-233 and RP-183. We are required to pay a single-digit royalty on net sales of the licensed products on a country-by-country basis. Pursuant to the license agreement, we are also required to make cash milestone payments upon successful completion of certain clinical, regulatory and commercial milestones up to an aggregate amount of $ 47.0 million for the first three indications of the licensed product with a maximum payment amount of $ 100.0 million. In 2019, we entered into a first amendment to the convertible promissory note with Riptide. Under the agreement, we extended the maturity of the promissory note to the earlier of (a) the later of (i) the completion of non-clinical IND enabling studies by the company, or (ii) December 31, 2020; and (b) when we accelerate the maturity of the note upon the occurrence of an event of default. No other terms and conditions of the promissory note were modified. Concurrently, we also entered into a first amendment to the exclusive license agreement with Riptide and extended the achievement dates for certain clinical trial milestones related to the licensed products. The convertible note receivable balance was $ 7.4 million and $ 7.1 million, which included accrued interest of $ 2.4 million and $ 2.1 million as of December 31, 2025 and 2024, respectively. 190 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consist of the following (in thousands): As of December 31, 2025 2024 Accrued bonus $ 14,348 $ 10,346 Accrued professional and service fees 7,512 16,849 Accrued sales costs 6,308 530 Accrued compensation 5,720 4,679 Accrued preclinical and clinical trial costs 5,491 2,876 Accrued research and development costs 2,635 3,002 Financing obligation 1,751 1,248 Other 3,073 1,050 Accrued expenses and other liabilities $ 46,838 $ 40,580 8. Financial Instruments Investments in Marketable Debt Securities As of December 31, 2025 and 2024, the remaining contractual maturities, amortized cost, gross unrealized gains, gross unrealized losses, and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in thousands): December 31, 2025 Remaining Contractual Maturities Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Treasury securities 0.4 $ 154,383 $ 101 $ — $ 154,484 December 31, 2024 Remaining Contractual Maturities Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Treasury securities 0.3 $ 6,094 $ 2 $ — $ 6,096 As of December 31, 2025 and 2024, all contractual maturities of marketable debt securities were 12 months or less. As of December 31, 2025 and 2024, no marketable debt securities were in an unrealized loss position. During the years ended December 31, 2025, 2024 and 2023, we evaluated our securities for other-than-temporary impairment and did not recognize any other-than-temporary impairment losses. Investments in Marketable Equity Securities We held investments in marketable equity securities with readily determinable fair value. See Note 9 “ Fair Value Measurements ” for more information. 191 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Investment in Other Equity Security In August 2024, the company entered into a SAFE with an unrelated party in exchange for the right to acquire certain shares of the investee. Upon the closing of equity financing by the investee prior to the termination of the SAFE, the SAFE will convert into preferred shares. We elected to apply the measurement alternative under FASB ASC Topic 321, Investments—Equity Securities , pursuant to which we measure our investment in the SAFE at cost, less impairment. As of December 31, 2025 and 2024, we held an investment in the SAFE of $ 0.7 million in other assets , on the consolidated balance sheets. We evaluate this investment for any indications of impairment in value on a quarterly basis. No factors indicative of impairment were identified during the years ended December 31, 2025 and 2024. Interest and Investment Income, Net Interest and investment income (loss), net consists of the following (in thousands): Year Ended December 31, 2025 2024 2023 Investment accretion income, net $ 4,008 $ 6,249 $ 1,844 Interest income 2,689 2,400 863 Net realized (losses) gains on investments ( 292 ) ( 42 ) 15 Unrealized losses from equity securities — ( 632 ) ( 1,591 ) Interest and investment income, net $ 6,405 $ 7,975 $ 1,131 Interest income includes interest from marketable securities, a convertible note receivable, other assets, and on bank deposits. Investment accretion income (amortization expense), net includes accretion of discounts (amortization of premiums) from securities classified as cash equivalents and marketable debt securities. 192 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) 9. Fair Value Measurements Recurring Valuations Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in thousands): Fair Value Measurements at December 31, 2025 Total Level 1 Level 2 Level 3 Assets at Fair Value: Current: Cash and cash equivalents $ 88,334 $ 88,334 $ — $ — U.S. Treasury securities 154,484 154,484 — — Noncurrent: Restricted cash 1,097 1,097 — — Total assets measured at fair value $ 243,915 $ 243,915 $ — $ — Liabilities at Fair Value: Current: Contingent consideration $ ( 22 ) (1) $ — $ — $ ( 22 ) Noncurrent: Related-party convertible note payable at fair value ( Note 14 ) ( 477,093 ) — — ( 477,093 ) Warrant liabilities ( Note 16 ) ( 84,417 ) — — ( 84,417 ) RIPA derivative liability ( Note 13 ) ( 19,400 ) — — ( 19,400 ) Stock option purchase liability ( Note 13 ) ( 322 ) — — ( 322 ) Total liabilities measured at fair value $ ( 581,254 ) $ — $ — $ ( 581,254 ) 193 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Fair Value Measurements at December 31, 2024 Total Level 1 Level 2 Level 3 Assets at Fair Value: Current: Cash and cash equivalents $ 143,428 $ 143,428 $ — $ — U.S. Treasury securities 6,096 6,096 — — Equity securities 285 285 — — Total assets measured at fair value $ 149,809 $ 149,809 $ — $ — Liabilities at Fair Value: Current: Contingent consideration $ ( 19 ) (1) $ — $ — $ ( 19 ) Noncurrent: Related-party convertible note payable at fair value ( Note 14 ) ( 461,877 ) — — ( 461,877 ) RIPA derivative liability ( Note 13 ) ( 25,800 ) — — ( 25,800 ) Warrant liabilities ( Note 16 ) ( 8,575 ) — — ( 8,575 ) Stock option purchase liability ( Note 13 ) ( 320 ) — — ( 320 ) Total liabilities measured at fair value $ ( 496,591 ) $ — $ — $ ( 496,591 ) _______________ (1) Contingent consideration is recorded at estimated fair value and revalued each reporting period until the related contingency is resolved. The fair value measurement is based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level 3 measurement within the fair value hierarchy) and are reviewed periodically by management. See Note 11 “Commitments and Contingencies—Contingent Consideration Related to Business Combinations” for more information. Changes in fair value of contingent consideration were immaterial during the years ended December 31, 2025 , 2024 and 2023, and were primarily due to changes in foreign currency exchange rates. Non-Recurring Valuations Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. Except for the impairments discussed in Note 6 “Goodwill and Intangible Assets, Net” there were no other non-financial assets or liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis during the years ended December 31, 2025, 2024 and 2023. We measured the fair value of the promissory notes and the embedded conversion features as of December 10, 2024, December 29, 2023 and September 11, 2023, respectively, upon debt amendments to determine the accounting treatment, using a “with-and-without” method. We used binomial lattice models for the “with” scenario and discounted cash flow analyses for the “without” scenario. Since certain of the factors analyzed are considered to be unobservable inputs, both the lattice model and the discounted cash flow model are considered to be a Level 3 valuation. See Note 14 “Related-Party Debt” for more information. 194 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) 10. Collaboration and License Agreements Collaboration Agreements National Cancer Institute The company and its subsidiaries began their relationship with HHS, as represented by the NCI of the NIH in 2015. Pursuant to the CRADAs, the NCI provides scientific staff and other support necessary to conduct research and related activities as described in the CRADAs. During the term of the initial and amended CRADAs, we collaborated with the NCI on the preclinical and clinical development of our proprietary adenovirus technology expressing TAAs for cancer immunotherapy. In 2021, the CRADA was amended through May 2026, and the research plan was modified to include the preclinical and clinical development of ImmunityBio’s proprietary adenovirus platform expressing TAAs, proprietary agent ANKTIVA and derivatives, an antibody-based cytokine fusion protein and derivatives and/or TxM product candidates, proprietary recombinant NK cells and mAbs, proprietary adjuvants, and other proprietary agents owned or controlled by ImmunityBio for cancer immunotherapy. Under this agreement, we agreed to pay NCI funding totaling $ 1.3 million per year, payable in semi-annual installments each year through 2025. During the years ended December 31, 2025, 2024, and 2023, we recorded $ 1.3 million in research and development expense, on the consolidated statements of operations. Under the CRADA, any party may unilaterally terminate the agreement by providing timely advance written notice to the other party before the desired termination date. Pursuant to the terms of the CRADA, we have an option to elect to negotiate an exclusive or non-exclusive commercialization license to any inventions discovered in the performance of the CRADA. The parties jointly own any inventions and materials that are jointly produced by employees of both parties in the course of performing activities under the CRADA. Amyris Joint Venture In 2021, ImmunityBio and Amyris entered into a 50:50 joint venture arrangement and formed a new limited liability company to conduct the business of the joint venture. The purpose of the joint venture is to accelerate commercialization of a next-generation COVID-19 vaccine utilizing an RNA vaccine-platform. As part of the limited liability agreement, Amyris contributed $ 1.0 million in cash and rights to its license agreement with AAHI for an RNA platform for the field of COVID-19. ImmunityBio contributed $ 1.0 million in cash and priority access to its manufacturing capacity for the joint venture product. Both parties agreed to enter into a separate manufacturing and supply agreement and a sublicense agreement following the execution of the joint venture agreement. The joint venture agreement stipulates the initial terms for equal representation in the management of the newly-formed joint venture. The joint venture is managed by a board of directors consisting of four directors: two appointed by the company and two appointed by Amyris. Both parties agreed to make additional capital contributions in cash, in proportion to their respective interests, as determined by the board of directors of the joint venture. We considered the joint venture entity as a VIE and determined that we are not the primary beneficiary of the VIE. We account for our investment in the joint venture using the equity method of accounting. During the year ended December 31, 2023, we recorded our 50 % share of net losses from the joint venture totaling $ 7.5 million in other income (expense), net , on the consolidated statement of operations. During the year ended December 31, 2023, such losses incurred included $ 7.5 million attributable to expenses incurred by us on behalf of the joint venture. We are not obligated to fund the joint venture’s potential future losses. In August 2023, Amyris announced that it filed for Chapter 11 bankruptcy protection. The Amyris bankruptcy case remains ongoing, and there can be no assurance that we will receive any recovery on account of our claims against Amyris, including for Amyris’ portion of expenses incurred by the joint venture. As of December 31, 2025, the carrying amount of our equity investment in the joint venture was zero . 195 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) License Agreements 3M IPC and AAHI License Agreement We have licensed rights to 3M-052, a synthetic TLR7/8 agonist, 3M-052 formulations and related technology from 3M IPC and its affiliates and AAHI. In 2021 we obtained nonexclusive rights in the field of SARS-CoV-2, and in June 2022 we modified those rights and expanded the scope of the license to include (1) SARS-CoV-2 and other infectious diseases including malaria, HIV, tuberculosis, hookworm and varicella zoster on an exclusive basis in countries other than LMIC, and (2) oncology applications, when used in combination with our proprietary technology and/or IL-15 receptor superagonist. In consideration for the license, we agreed to make certain periodic license payments, including $ 2.25 million each year through June 2025. We have also agreed to make payments upon the achievement of certain regulatory milestone events and tiered royalties ranging from the low to high single-digits as a percentage of net sales. As of December 31, 2025, no such sales have been made and no such regulatory milestone events have been achieved. Beginning in April 2026, the annual minimum licensing payment is $ 1.0 million, which can be credited against any royalty payments due under this agreement. During the years ended December 31, 2025 and 2024, we recorded $ 2.3 million, respectively, and $ 2.0 million during the year ended December 31, 2023 in research and development expense , on the consolidated statements of operations. AAHI Agreements In 2021, ImmunityBio and AAHI entered into several agreements, including an RNA vaccine platform license agreement, an adjuvant formulation license agreement, and a sponsored research agreement (collectively, the “AAHI Agreements”). ImmunityBio is no longer pursuing development of the AAHI RNA platform and related technology it had licensed from AAHI in 2021. During the second half of 2024, the parties reached an agreement whereby ImmunityBio would owe no future payments to AAHI under the AAHI Agreements, ImmunityBio would return the licenses to AAHI, the AAHI Agreements were terminated, and each party mutually released and had no continuing obligations to the other. With respect to the license agreements, we recorded $ 2.3 million and $ 4.5 million, respectively, in research and development expense , on the consolidated statements of operations during the years ended December 31, 2024 and 2023. During the year ended December 31, 2025, we recorded no expense related to these agreements. With respect to the sponsored research agreement, we recorded $ 1.2 million in research and development expense , on the consolidated statement of operations related to the sponsored research agreement during the year ended December 31, 2023. During the years ended December 31, 2025 and 2024, we recorded no expense related to this agreement. 11. Commitments and Contingencies Contingent Consideration Related to Business Combinations VivaBioCell, S.p.A. In April 2015, NantWorks, a related party, acquired a 100 % interest in VivaBioCell through its wholly-owned subsidiary, VBC Holdings for $ 0.7 million, less working capital adjustments. In June 2015, NantWorks contributed its equity interest in VBC Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. In connection with our acquisition of VBC, we are obligated to pay the former owners contingent consideration upon the achievement of certain milestones related to the GMP-in-a-Box technology. If a government agency unconditionally approves the GMP-in-a-Box technology for commercial sale (the regulatory milestone) in the future, we will be obligated to pay an additional approximately $ 2.3 million to the former owners. 196 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Altor BioScience, LLC In connection with our 2017 acquisition of Altor, we issued CVRs under which we agreed to pay the prior stockholders of Altor approximately $ 304.0 million of contingent consideration upon calendar-year worldwide net sales of ANKTIVA exceeding $ 1.0 billion prior to December 31, 2026, with amounts payable in cash or shares of our common stock or a combination thereof. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable. As of December 31, 2025, Dr. Soon-Shiong, our Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and his related party hold approximately $ 139.8 million of net sales CVRs, and they have both irrevocably agreed to receive shares of the company’s common stock in satisfaction of their CVRs. We may be required to pay the other prior Altor stockholders up to $ 164.2 million for their net sales CVRs should they choose to have their CVRs paid in cash instead of common stock. Litigation From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Sorrento Therapeutics, Inc. Litigation Sorrento, derivatively on behalf of NANTibody, filed an action in the Superior Court of California, Los Angeles County (the Superior Court) against the company’s subsidiary NantCell, Dr. Soon-Shiong, and Charles Kim. The action alleged that the defendants improperly caused NANTibody to acquire IgDraSol from NantPharma, LLC and sought to have the transaction undone and the purchase amount returned to NANTibody. In 2019, we filed a demurrer to several causes of action alleged in the Superior Court action, and Sorrento filed an amended complaint, eliminating Mr. Kim as a defendant and dropping the causes of action we had challenged in our demurrer. Trial had been set to commence in Sorrento’s Superior Court action on August 7, 2023, but on July 24, 2023 the Superior Court vacated the August 7, 2023 trial date at the parties’ request in light of the pending settlement discussed below. Also in 2019, the company and Dr. Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. Our claims alleged that Dr. Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento’s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement. The Superior Court ruled that the company’s claims should be pursued in arbitration and that Dr. Soon-Shiong’s claims could be pursued in Superior Court. In 2019, the company, along with NANTibody, filed an arbitration against Sorrento and Dr. Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration. The hearings in the NANTibody arbitration commenced in April 2021 and concluded in early August 2021. After post-hearing briefing was concluded, the parties were notified on November 30, 2021 that the arbitrator in the NANTibody arbitration had passed away. A substitute arbitrator was appointed on February 25, 2022, and the parties worked with the substitute arbitrator to conclude the proceedings. Additional hearing sessions were held in May and July 2022, and summations took place on August 2, 2022. On December 2, 2022, the arbitrator issued a final award finding that Sorrento had breached the two exclusive license agreements with NantCell and NANTibody. The arbitrator awarded NantCell approximately $ 156.8 million and NANTibody approximately $ 16.7 million, plus post-award interest accruing at a daily rate. On December 21, 2022, NantCell and NANTibody filed petitions in the Superior Court to confirm the arbitration award; on January 16, 2023, Sorrento filed a response to the petitions and moved to vacate the award. On February 7, 2023, after a hearing, the Superior Court entered orders confirming the arbitration award and denying Sorrento’s motion to vacate. The Superior Court entered judgments against Sorrento in the 197 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) aggregate amount of approximately $ 176.4 million plus 10 % post-judgment interest, of which approximately $ 159.4 million was payable to NantCell, and the remainder of which was payable to NANTibody. On February 13, 2023, Sorrento informed counsel to the company that it had filed a Chapter 11 proceeding in the United States District Court for the Southern District of Texas, In re: Sorrento Therapeutics, Inc., et al., Case No. 23-90085 (DRJ), Docket Entry 810. On June 6, 2023, Sorrento filed a motion in its Chapter 11 proceeding for entry of an order approving and implementing a mediation settlement reached with the company and other entities. The settlement involved two possible scenarios: Either, if Sorrento were to raise an amount needed to pay its debtor in possession lender and its unsecured creditors by August 31, 2023, Sorrento would pay those obligations, including the judgments held by NantCell and NANTibody, by 2:00 p.m. ET on August 31, 2023 and be free to proceed with pending litigation; or, failing that, the judgments would be released, the litigation claims would be released, including, without limitation, the Superior Court action discussed above, Sorrento would relinquish its interests in NANTibody and certain other entities, Sorrento would forfeit its rights to any payments from NantCell arising out of its antibody exclusive license agreement with NantCell (rights to PD-L1), and certain other provisions not impacting the company would be implemented as described in the motion. On August 14, 2023, the United States Bankruptcy Court for the Southern District of Texas issued an order approving the settlement described above, such that the settlement became binding on the parties. As of 2:00 p.m. ET on August 31, 2023, Sorrento had not paid the judgments held by NantCell and NANTibody. Accordingly, in relevant part to the company and NantCell, a mutual release of claims became effective such that the aforementioned judgments were released, the litigation claims were released including, without limitation, the derivative litigation against NantCell described above, Sorrento relinquished its interests in NANTibody, and Sorrento forfeited its rights to any payments from NantCell arising out of its antibody exclusive license agreement with NantCell, including any royalties associated with the company’s engineered NK cell therapy in Phase 2 clinical trials, PD-L1 t-haNK. As a result of the settlement, the parties filed dismissals of the litigation matters discussed above. After the settlement, the company’s ownership in NANTibody increased from 60 % to 100 %, and, as a result, the carrying amount of the noncontrolling interest of $ 4.2 million was adjusted and recognized in additional paid-in capital attributable to the company, on the consolidated statement of stockholders’ deficit. Shenzhen Beike Biotechnology Co. Ltd. Arbitration In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration. The arbitration relates to a license, development, and commercialization agreement that Altor entered into with Beike in 2014, which was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on ANKTIVA in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to ANKTIVA. Beike is seeking specific performance and declaratory relief for the alleged breaches. On September 25, 2020, the parties entered into a standstill and tolling agreement (standstill agreement) under which, among other things, the parties affirmed they will perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement could be terminated by any party on ten calendar days’ notice, and upon termination, the parties had the right to pursue claims arising from the license agreement in any appropriate tribunal. On March 20, 2023, we terminated the standstill agreement, and on April 11, 2023, Beike served an amended Request for Arbitration. We served an Answer and Counterclaims on May 19, 2023. Beike served a Reply to our counterclaims on June 21, 2023. Beike served its Statement of Claim on March 22, 2024, the company served its Statement of Defense and Counterclaim on June 21, 2024, and Beike served its Statement of Defense to the Counterclaim on August 2, 2024. After the parties completed discovery, Beike served its Reply and Defense to Counterclaim on January 17, 2025, we served our Rejoinder and Response to Defense to Counterclaim on March 14, 2025, and Beike served its Rejoinder on Counterclaim on March 28, 2025. The hearing in the arbitration was held from June 9, 2025 through June 13, 2025. Post-hearing submissions concluded in February 2026. It remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims asserted against the company lack merit. 198 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Securities Class Action On June 30, 2023, a putative securities class action complaint, captioned Salzman v. ImmunityBio, Inc. et al. , No. 3:23-cv-01216-GCP-VET, was filed in the United States District Court for the Southern District of California against the company and three of its officers and/or directors, asserting violations of Sections 10(b) and 20(a) of the Exchange Act. Stemming from the company’s disclosure on May 11, 2023 that it had received an FDA CRL stating, among other things, that it could not approve the company’s BLA for its then product candidate, ANKTIVA with BCG for the treatment of adult patients with BCG-unresponsive NMIBC CIS with or without papillary tumors, in its present form due to deficiencies related to its pre-license inspection of the company’s third-party CMOs, the complaint alleges that the defendants had previously made materially false and misleading statements and/or omitted material adverse facts regarding its third-party CMOs and the prospects for regulatory approval of the BLA. The complaint did not specify the amount of damages being sought. On September 27, 2023, the court appointed a lead plaintiff, approved their selection of lead counsel, and re-captioned the case In re ImmunityBio, Inc. Securities Litigation, No. 3:23-cv-01216. On November 17, 2023, the lead plaintiff filed an amended complaint, which named the same defendants and asserted the same claims as the previous complaint. On January 8, 2024, the defendants filed a motion to dismiss the amended complaint. On June 20, 2024, the court issued an order granting in part and denying in part the motion to dismiss. On July 16, 2024, the lead plaintiff notified the court that he would proceed with his current pleading, and the defendants answered the complaint on August 29, 2024. On January 25, 2025, following a mediation and the parties’ agreement in principle to settle the securities class action for $ 10.5 million, the lead plaintiff filed an unopposed motion for preliminary approval of class action settlement. On March 17, 2025, the court granted preliminary approval of the settlement. On June 16, 2025, following a final approval hearing, the court granted final approval of the settlement. The lawsuit is now fully resolved. As a result of the foregoing, the company recorded legal settlement expense of $ 10.5 million in selling, general and administrative expense, on the consolidated statement of operations during the year ended December 31, 2024 and a corresponding amount in accrued expenses and other liabilities , on the consolidated balance sheet. During the year ended December 31, 2025, the company settled in full the amount due under the settlement agreement. Of the $ 10.5 million, approximately $ 6.0 million were paid by the company’s insurers. The company paid the remaining $ 4.5 million under the settlement agreement. Van Luven, Barbieri and Shin Derivative Actions On October 29, 2024, a shareholder derivative action was filed in the United States District Court for the Southern District of California against the members of our Board of Directors and certain officers, captioned Van Luven v. Soon-Shiong et al. , Case No. 3:24-cv-02014-GPCL-VET. The plaintiff purports to bring the action derivatively on behalf of ImmunityBio, and ImmunityBio is a nominal defendant to the action. Stemming from the company’s May 11, 2023 disclosure that it had received an FDA CRL stating, among other things, that it could not approve the company’s BLA for its then product candidate, ANKTIVA with BCG for the treatment of adult patients with BCG-unresponsive NMIBC CIS with or without papillary tumors, in its present form due to deficiencies related to its pre-license inspection of the company’s third-party CMOs, the derivative complaint alleges that the individual defendants authorized or permitted materially false and misleading statements and/or omitted material adverse facts regarding ImmunityBio’s third-party CMOs and the prospects for regulatory approval of the ANKTIVA BLA. The derivative complaint asserts claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duty, unjust enrichment, and waste of corporate assets. The derivative complaint seeks unspecified damages on behalf of the company, disgorgement or restitution, declaratory relief, and an award of costs and expenses to the derivative plaintiff, including attorneys’ fees. The court entered an order extending the defendants’ deadline to respond to the complaint to May 30, 2025. On February 25, 2025, a second shareholder derivative action was filed in the United States District Court for the Southern District of California against certain members of our Board of Directors and certain officers, captioned Barbieri v. Soon-Shiong, et al ., Case No. 3:25-cv-00416-AGS-JLB. The plaintiff purports to bring the action derivatively on behalf of ImmunityBio, and ImmunityBio is a nominal defendant in the action. This lawsuit asserts substantially similar claims and allegations as Van Luven . The court entered an order extending the defendants’ deadline to respond to the complaint to May 30, 2025. 199 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) On February 26, 2025, a third shareholder derivative action was filed in the United States District Court for the Southern District of California against certain current and former members of our Board of Directors and certain officers, captioned Shin v. Soon-Shiong, et al. , Case No. 3:25-cv-00423-JAH-DDL. The plaintiff purports to bring the action derivatively on behalf of ImmunityBio, and ImmunityBio is a nominal defendant in the action. This lawsuit asserts substantially similar claims and allegations as Van Luven . The court entered an order extending the defendants’ deadline to respond to the complaint to May 30, 2025. On May 2, 2025, the court entered an order consolidating these three shareholder derivative actions. On May 22, 2025, the parties in the consolidated derivative action notified the court that they had entered into a Stipulation and Settlement Agreement to settle the consolidated derivative action for corporate governance reforms and attorneys’ fees. On November 6, 2025, the court entered an order and final judgment approving the settlement. As a result of the final judgment, the company was required to make various corporate governance modifications in which the company complied with. Carlson Derivative Action On November 20, 2024, a shareholder derivative action was filed in the Delaware Court of Chancery against the company’s Founder, Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder, Dr. Soon-Shiong, certain affiliates of Dr. Soon-Shiong, certain other members of management, and members of the company’s Board of Directors who serve on the Board of Directors’ Related Party Transaction Committee, captioned Carlson v. Soon-Shiong, et al., Case No. 2024-1195-VCL. The plaintiff purports to bring the action derivatively on behalf of ImmunityBio, and ImmunityBio is a nominal defendant to the action. The plaintiff alleges that the previously disclosed September 2023 financing transactions between the company and Dr. Soon-Shiong and his affiliates were not fair to the company. In particular, the plaintiff alleges that the transactions were timed to benefit Dr. Soon-Shiong and his affiliates during a temporary decline in the company’s stock price, resulting in an artificially low conversion price for certain convertible promissory notes that were among the transactions, when defendants knew the company’s stock price would increase following the company’s imminent resubmission of a BLA for, and the subsequent FDA approval of, ANKTIVA with BCG for the treatment of adult patients with BCG-unresponsive NMIBC CIS with or without papillary tumors. The complaint alleges that defendants breached their fiduciary duties by entering into these transactions at that time and on those terms, thereby unjustly enriching Dr. Soon-Shiong and his affiliates. The derivative complaint seeks unspecified damages on behalf of the company, corporate governance changes with respect to related-party transactions, and an award of costs and expenses to the derivative plaintiff, including attorneys’ fees. On February 17, 2025, the defendants filed a motion to dismiss the complaint. On May 2, 2025, instead of filing an opposition to defendants’ motion to dismiss, the plaintiff filed an amended complaint. This amended complaint added certain additional members of the company’s Board of Directors as defendants but did not add new claims. On July 16, 2025, the defendants filed a motion to dismiss the amended complaint. On February 4, 2026, after complete briefing and oral argument, the court granted the defendants’ motion to dismiss. The plaintiff was not provided an opportunity to amend. SRS/Altor Shareholder CVR Arbitration In connection with our 2017 acquisition of Altor, we issued CVRs under which we agreed to pay the prior stockholders of Altor approximately $ 304.0 million of contingent consideration upon the successful regulatory approval of a BLA by the FDA, or foreign equivalent, for ANKTIVA by December 31, 2022, and $ 304.0 million of contingent consideration upon calendar-year worldwide net sales of ANKTIVA exceeding $ 1.0 billion prior to December 31, 2026. As of December 31, 2025, Dr. Soon-Shiong, our Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and his related party hold approximately $ 139.8 million of FDA approval CVRs and $ 139.8 million of net sales CVRs, and they have both irrevocably agreed to receive shares of the company’s common stock in satisfaction of their CVRs. Because the FDA did not approve our BLA on or before December 31, 2022, the first CVR milestone was not met. 200 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) On December 27, 2022, Shareholder Representative Services, LLC (SRS), in its capacity as shareholder representative on behalf of former Altor BioScience Corp. shareholders, sent the company’s subsidiary NantCell a notice of claims relating to the regulatory milestone CVR. The notice of claims asserted that SRS was exploring, and might pursue, claims on behalf of Altor shareholders for additional merger consideration in the amount of the $ 2.00 per share milestone payment under the regulatory CVR milestone. The notice stated that any such claim would be based on NantCell’s alleged failure to use commercially reasonable efforts to secure FDA approval of ANKTIVA on or before December 31, 2022. In a separate October 2022 letter, SRS requested that NantCell preserve all documents and information relating to its efforts to achieve milestones set forth in the regulatory milestone CVR, and requested that the company provide certain categories of documents under the information-sharing provisions of the CVR agreement. After the company provided many of the requested documents, on September 29, 2023, SRS filed a demand for arbitration with JAMS, seeking to compel the company to produce additional documents identified in its October 2022 letter relating to its efforts to obtain FDA approval for ANKTIVA. The arbitration demand did not include any claims beyond SRS’s claim that it had a right to obtain additional documents, and sought a ruling that the company was obligated to provide additional documents. After the arbitrator issued a preliminary ruling regarding the scope of the company’s obligation to provide information under the CVR Agreements, the company produced additional documents responsive to SRS’s requests. On August 27, 2025, several months after SRS’s document-access claim had been resolved, SRS requested leave to amend its JAMS arbitration demand to state a claim for breach of contract. SRS’s proposed amended demand alleged that the company and NantCell had failed to exercise commercially reasonable efforts to obtain FDA approval ANKTIVA on or before December 31, 2022. The JAMS arbitrator presiding over the document-access arbitration denied SRS’s motion for leave to amend its claims, and on September 26, 2025, the parties filed a joint stipulation asking that the JAMS document-access arbitration be closed. After SRS’s motion for leave to amend was denied, on September 26, 2025, SRS sent the company a further notice of claims and essentially the same arbitration demand, asserting that the company had breached its obligations to exercise commercially reasonable efforts to achieve FDA approval of ANKTIVA on or before December 31, 2022. SRS’s arbitration demand seeks relief in the form of payment, in the amount of approximately $ 164.2 million plus interest exceeding $ 50.0 million, to former Altor shareholders not affiliated with Dr. Soon-Shiong. SRS filed its most recent arbitration demand with JAMS on November 5, 2025. The company filed its response on November 19, 2025, and an arbitrator was appointed on January 16, 2026. It remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the company exercised commercially reasonable efforts in its pursuit of FDA approval of ANKTIVA, and that the claims asserted against the company lack merit. Dunkirk Facility Leasehold Interest In 2022, we completed the acquisition of the Dunkirk Facility (approximately 409,000 rentable square feet) from Athenex. We believe this facility has the potential to provide us with a state-of-the-art biotech production center that will expand and diversify our existing manufacturing capacity in the U.S. and the ability to scale production associated with certain of our product candidates. The company accounted for the transaction as an asset acquisition because the Dunkirk Facility’s integrated set of assets and activities does not meet the definition of a business. Upon the closing of the Dunkirk transaction, the company became the tenant of the Dunkirk Facility under the Fort Schuyler Management Corporation Lease, dated October 1, 2021 and as amended as of the February 14, 2022 closing date (as amended, the Dunkirk Lease), with the FSMC as landlord. The Dunkirk Facility, as well as certain equipment, is owned by the FSMC and is leased to us under the Dunkirk Lease. We believe that the Dunkirk Facility has construction needs that may require approximately 12 to 18 months to complete in order for it to be used as intended as a result of an ongoing dispute with the Dunkirk Facility’s general contractor and a stay in resolving the dispute related to Athenex’s ongoing bankruptcy proceedings. 201 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) In December 2025, we entered into a second amendment to the Dunkirk Lease (the “second amendment”). Under the second amendment, the annual lease payment was increased to $ 0.5 million for a revised lease term through December 31, 2028. The company has the option to purchase the Dunkirk Facility at $ 1.00 on either January 1, 2028, or January 1, 2029. The second amendment was accounted for as a modification of a single lease contract. The lease is classified as an operating lease. As of December 31, 2025, we recognized an operating right-of-use lease asset and lease liability of $ 1.4 million, respectively, on the consolidated balance sheet. See Note 12 “ Lease Arrangements ” for more information. The second amendment also removed the original spending obligations assumed from Athenex totaling $ 1.52 billion and replaced them with a series of spending targets totaling $ 55.0 million, including minimum of $ 40.0 million cumulative capital spending to be complied through December 31, 2028, and minimum of $ 5.0 million of annual operating spending to be complied from 2026 to 2028. As of December 31, 2025, we are in compliance with the requirements of such targets. We also agreed to meet certain headcount targets by hiring at least 100 full-time employees by the end of the three-year term of the amended lease. If the option to purchase is exercised, we are required to hire at least 450 full-time employees by December 31, 2032 through December 31, 2033; and we are prohibited from conveying the premises for a five-year period without obtaining the prior written consent of FSMC and Empire State Development. Unconditional Purchase Obligations Unconditional purchase obligations are defined as an agreement to purchase goods or services that are enforceable and legally binding (non-cancelable, or cancellable only in certain circumstances). Estimated future minimum unconditional purchase obligations as of December 31, 2025 are as follows (in thousands): Years Ending December 31, 2026 2027 2028 2029 2030 Software license fees and installation costs $ 7,312 $ 916 $ 159 $ 93 $ — Facilities services 732 — — — — Reserved cGMP manufacturing capacity at third-party CMO facilities 396 — — — — Commercial launch and product services 199 — — — — Other 73 73 73 — — The purchase obligation amounts do not represent the entire anticipated purchases in the future but represent only those items for which we are contractually obligated. The majority of our goods and services are purchased as needed, with no unconditional commitment. For this reason, these amounts do not provide an indication of our expected future cash outflows related to purchases. Commitments During the year ended December 31, 2025, we did not enter into any significant contracts, other than those disclosed in these consolidated financial statements. In addition to those commitments already disclosed, we have conditional contractual commitments that are expected to be paid in fiscal year 2027 and beyond based on royalties on potential future net sales or the achievement of various development, regulatory, and commercial milestones for agreements with third parties. These payments may not be realized or may be modified and are contingent upon the occurrence of various future events, substantially all of which have a high degree of uncertainty of occurring. As of December 31, 2025, the maximum amount that may be payable related to the various development, regulatory, and commercial milestones commitments is $ 40.8 million. 202 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) 12. Lease Arrangements We lease property in multiple facilities across the U.S. and Italy, including facilities located in El Segundo, CA and the Dunkirk Facility in upstate New York. Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. Our finance leases are related to equipment rentals. See Note 15 “Related-Party Agreements” for more information about our related-party leases. Our leases generally have initial terms ranging from two to ten years and often include one or more options to renew. These renewal terms can extend the lease term from one to ten years and are included in the lease term when it is reasonably certain that we will exercise the option. Supplemental balance sheet information related to our leases is as follows (in thousands): As of December 31, Classification 2025 2024 Assets Operating lease assets (including amounts with related parties) Operating lease right-of-use assets $ 33,010 $ 33,363 Finance lease assets Other assets 271 — Total lease assets (including amounts with related parties) $ 33,281 $ 33,363 Liabilities Current: Operating lease liabilities (including amounts with related parties) Operating lease liabilities $ 7,535 $ 7,466 Finance lease liabilities Accrued expenses and other liabilities 52 — Noncurrent: Operating lease liabilities (including amounts with related parties) Operating lease liabilities, less current portion 33,447 34,823 Finance lease liabilities Other liabilities 227 — Total lease liabilities (including amounts with related parties) $ 41,261 $ 42,289 Information regarding our lease terms is as follows: Year Ended December 31, 2025 2024 Weighted-average remaining lease term: Operating leases 4.6 years 4.8 years Finance leases 4.4 years — Weighted-average discount rate: Operating leases 11.1 % 9.9 % Finance leases 11.6 % — % 203 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The components of lease expense consist of the following (in thousands): Year Ended December 31, 2025 2024 2023 Operating lease costs $ 10,537 $ 10,277 $ 11,123 Short-term lease costs 4,563 4,277 4,088 Finance lease costs (including right-of-use asset amortization and interest expense) 54 59 88 Variable lease costs 3,484 3,947 3,521 Total lease expense $ 18,638 $ 18,560 $ 18,820 Cash paid for amounts included in the measurement of lease liabilities is as follows (in thousands): Year Ended December 31, 2025 2024 2023 Cash paid for operating leases (excluding variable lease costs) $ 11,670 $ 10,642 $ 9,538 Financing cash flow from finance leases 28 64 77 Operating cash flow from finance leases 18 2 11 Future minimum lease payments as of December 31, 2025, including $ 11.5 million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in thousands). Common area maintenance costs and taxes are not included in these payments. Years Ending December 31: Operating Leases Finance Leases Total 2026 $ 11,400 $ 79 $ 11,479 2027 10,749 79 10,828 2028 11,052 79 11,131 2029 9,915 79 9,994 2030 7,522 34 7,556 Thereafter 1,200 — 1,200 Total future minimum lease payments 51,838 350 52,188 Less: Interest 10,856 71 10,927 Present value of lease liabilities $ 40,982 $ 279 $ 41,261 On May 27, 2025, we entered into an amendment to an existing operating lease of office space, which was initially scheduled to expire on December 31, 2025. We executed the first option to extend the lease through December 31, 2030, with no changes to any of the other terms of the lease. We have a second option to extend the lease for an additional five years . Management has identified this extension as a reassessment event as we elected to exercise the lease extension option, which was previously determined that it was not reasonably certain to do so. We reassessed the discount rate at the remeasurement date, at 11.8 % and we remeasured the operating lease right-of-use asset and operating lease liability on our consolidated balance sheet based on the reassessed discount rate, remaining lease term and lease payments. We determined that the lease extension has no effect on the classification of the lease. In addition, we also determined that the second option to extend the lease is not reasonably certain to be exercised. 204 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Prior to the extension, the remaining lease liability amounted to $ 0.6 million. On the date of the extension, we determined that the value of the new operating lease right-of-use asset and operating lease liability was $ 4.6 million, respectively. As such, as of June 30, 2025, the company recorded an increase in lease liability of $ 4.0 million because of the lease extension. During the year ended December 31, 2025, there have been no material changes related to our existing lease agreements. 13. Revenue Interest Purchase Agreement Revenue Interest Liability On December 29, 2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain initial Revenue Interests from us for a gross purchase price of $ 200.0 million paid on closing, less $ 7.5 million of issuance costs. Oberland had the option to purchase additional Revenue Interests from us in exchange for a $ 100.0 million Second Payment upon satisfaction of certain conditions in the RIPA, including receipt of approval from the FDA of our BLA for ANKTIVA on or before June 30, 2024. In April 2024, the FDA approved our product ANKTIVA and as a result, on May 13, 2024 Oberland purchased additional Revenue Interests from us for a gross purchase price of $ 100.0 million, less $ 3.1 million of issuance costs. The issuance costs incurred are being amortized to interest expense over the estimated term of the debt. As consideration for the aforementioned payments, Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, a certain percentage of our net sales during such quarter, which are tiered payments ranging from 4.5 % to 10.0 % (before funding of the Second Payment, 3.0 % to 7.0 %) of the company’s worldwide net sales, excluding those in China. If the aggregate Revenue Interest Payments made to Oberland as of December 31, 2029 (Test Date) equal or exceed the Cumulative Purchaser Payments ($ 300.0 million) as of that date, the initially tiered revenue interest rate will be decreased to a single rate of 2.25 % (before the funding of the Second Payment, 1.50 %) of the company’s worldwide net sales, excluding those in China. If the aggregate Revenue Interest Payments made to Oberland as of the Test Date are less than the aggregate amount of Cumulative Purchaser Payments as of the Test Date, then following the Test Date the initially tiered revenue interest rate will increase to a rate that, had such increased rate applied during the period from December 29, 2023 through December 31, 2029, it would have resulted in Oberland receiving aggregate Revenue Interest Payments (excluding certain payments detailed in the RIPA) equal to the Cumulative Purchaser Payments as of the Test Date. In addition, if aggregate Revenue Interest Payments made to Oberland as of the Test Date are less than the aggregate amount of Cumulative Purchaser Payments as of the Test Date, then the company must make the True-Up Payment. Oberland’s rights to receive Revenue Interest Payments under the RIPA shall terminate when Oberland has received payments (including any True-Up Payment) equal to 195.0 % of the then Cumulative Purchaser Payments unless the RIPA is terminated prior to such date (subject to certain Call/Put Option scenarios as described below). If Oberland has not received total payments (including any True-Up Payment) equal to 195.0 % of the then Cumulative Purchaser Payments on or before the twelfth anniversary of the RIPA, then the company shall be obligated to pay to Oberland an amount equal to 195.0 % of the then Cumulative Purchaser Payments less the aggregate payments (including any True-Up Payments) made as of such date. The company’s obligations under the RIPA are guaranteed by certain of its subsidiaries meeting materiality thresholds set forth in the RIPA. To secure the company’s obligations under the RIPA and the subsidiary guarantors’ obligations under the guarantees, each of the company and the subsidiary guarantors has granted a security interest in substantially all its assets, subject to certain exceptions and limitations. The RIPA contains affirmative and negative covenants and events of default, including covenants and restrictions that, among other things, restrict our ability to incur additional liens, incur additional indebtedness, make loans and investments, enter into transactions with affiliates, engage in mergers and acquisitions, engage in asset sales and exclusive licensing arrangements, and declare dividends to our stockholders, in each case, subject to certain exceptions set forth in the RIPA. As of December 31, 2025, the company was in compliance with all covenants. 205 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The RIPA is considered a sale of future revenues and is accounted for as long-term debt recorded at amortized cost using the effective interest rate method. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method. On December 10, 2024, the company entered into an amendment to the RIPA to add additional conditions to the payment of certain existing indebtedness. Such amendment did not have an impact on the valuation or financial statement classification of the revenue interest liability or the embedded derivative liabilities related to the RIPA. During the years ended December 31, 2025, 2024 and 2023, we recorded $ 51.5 million, $ 39.7 million and $ 0.3 million of interest expense, respectively, related to this arrangement. The following table summarizes the revenue interest liability activity during the years ended December 31, 2025 and 2024 (in thousands): Revenue interest liability, at December 31, 2023 $ 155,415 Proceeds from Second Payment, net of issuance costs 96,956 Interest expense recognized 39,657 Embedded contingent derivative liability related to Second Payment ( 6,150 ) Revenue interest payment ( 1,474 ) Revenue interest liability, at December 31, 2024 284,404 Interest expense recognized 51,540 Revenue interest payment ( 10,490 ) Accrued revenue interest payment ( 839 ) Revenue interest liability, at December 31, 2025 $ 324,615 Embedded Derivative Liabilities Under the RIPA, the company has a Call Option to terminate the RIPA and repurchase the Revenue Interests at any time upon advance written notice, subject to certain limitations set forth in the RIPA. Additionally, Oberland has a Put Option enabling them to terminate the RIPA and to require the company to repurchase the Revenue Interests upon enumerated events, such as a bankruptcy event, failure to make a payment, an uncured material breach, default in certain third-party agreements, a breach or default under any subordination agreements with respect to indebtedness to existing stockholders, or subordinated notes during certain time periods, judgments in excess of certain amounts against the company, a material adverse effect, the loss of regulatory approval of our product candidates or a change of control. The required purchase price with respect to the Call Option and/or Put Option, as applicable, shall be (a) 120.0 % of the Cumulative Purchaser Payments as of such date, if Oberland exercises the Put Option (other than in connection with a change of control) on or prior to the first anniversary the Closing Date, (b) 135.0 % of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised in connection with a change of control on or prior to the date that is eighteen (18) months after the Closing Date, and (c) in all other cases, (i) 175.0 % of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised no later than the date that is thirty six (36) months after the Closing Date, and (ii) 195.0 % of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised later than the date that is thirty six (36) months after the Closing Date, minus, in each case, the total payments made to Oberland on or prior to such date. 206 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The aforementioned Call and Put Options are considered embedded derivatives requiring bifurcation as a single compound derivative instrument. The company estimated the fair value of the derivative liability using a “with-and-without” method. The “with-and-without” methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the individual embedded derivative. The difference between the entire instrument with the embedded derivative compared to the instrument without the embedded derivative is the fair value of the derivative liability. The company recorded $ 34.5 million for the initial fair value of the derivative liability upon the closing of the initial $ 200.0 million Revenue Interests acquired by Oberland. The company recorded an incremental $ 6.2 million for the fair value of the derivative liability upon the closing of the additional $ 100.0 million Revenue Interests acquired by Oberland in May 2024. The initial and incremental fair value allocated to the derivative liability is recorded against the RIPA as a debt discount, which is being amortized in interest expense, on the consolidated statement of operations over the expected term of the debt using the effective interest method. Such embedded derivative is classified in derivative liabilities, on the consolidated balance sheet. The embedded derivative is subsequently remeasured at fair value each reporting period using a Monte Carlo Simulation valuation technique, with the change in fair value being recorded in change in fair value of derivative liabilities , on the consolidated statement of operations. The estimated probability and timing of underlying events triggering the exercisability of the Put Option contained in the RIPA, forecasted cash flows and the discount rate are significant unobservable inputs used to determine the estimated fair value of the entire instrument with the embedded derivative. As of December 31, 2025 and 2024, the discount rate used for valuation of the derivative liability was 11.7 % and 10.4 %, respectively. The change in fair value of the derivative liability is as follows (in thousands): Fair value, at December 31, 2023 $ 34,500 Change in fair value ( 14,850 ) Embedded contingent derivative liability related to Second Payment 6,150 Fair value, at December 31, 2024 25,800 Change in fair value ( 6,400 ) Fair value, at December 31, 2025 $ 19,400 Stock Purchase and Option Agreement In connection with the RIPA, we entered into a SPOA with Oberland pursuant to which we sold an aggregate of approximately $ 10.0 million of our common stock at $ 4.1103 per share in a private placement. Oberland also had an option to purchase up to an additional $ 10.0 million of our common stock, at a price per share to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. This stock purchase option was classified as a liability estimated at fair value at issuance. The initial $ 200.0 million received pursuant to the RIPA and $ 10.0 million received pursuant to the SPOA were allocated among the resulting financial instruments on a relative fair value basis, with $ 197.1 million allocated to the debt under the RIPA, $ 12.0 million allocated to the common stock issued under the SPOA, and $ 0.8 million allocated to the stock purchase option as of December 31, 2023. In April 2024, Oberland exercised part of their option and purchased 858,990 shares of our common stock at an exercise price of $ 5.8208 per share generating net proceeds of approximately $ 4.9 million. In relation to this transaction, we recorded $ 7.6 million in additional paid-in capital, on the statement of stockholders’ deficit during the year ended December 31, 2024. Following such exercise, approximately $ 5.0 million remains available for future exercise under the SPOA as of December 31, 2025. This option expires on December 29, 2028. This stock purchase option is classified in derivative liabilities , on the consolidated balance sheet at its fair value and is subsequently remeasured at fair value each reporting period, with the change in fair value being recorded in change in fair value of derivative liabilities , on the consolidated statement of operations. 207 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The estimated fair value of the stock option purchase liability was computed using a Monte Carlo Simulation valuation technique that used the calculated exercise price and discounted it back to a present value at the risk-free rate with the following unobservable input at the following dates: As of December 31, 2025 2024 Expected volatility 119.7 % 127.0 % The change in fair value of the stock option purchase liability is as follows (in thousands): Fair value, at December 31, 2023 $ 819 Exercise of stock option ( 2,705 ) Change in fair value 2,206 Fair value, at December 31, 2024 320 Change in fair value 2 Fair value, at December 31, 2025 $ 322 14. Related-Party Debt Our related-party debt is summarized below (in thousands): Balance as of December 31, 2025 Fair Value Maturity Year Interest Rate Principal Amount Amount Leveling Related-Party Convertible Note at Fair Value: $ 505 million December 2024 Promissory Note 2027 Term SOFR + 8.0 % $ 505,000 $ 477,093 Level 3 Balances as of December 31, 2024 Fair Value Maturity Year Interest Rate Principal Amount Amount Leveling Related-Party Convertible Note at Fair Value: $ 505 million December 2024 Promissory Note 2027 Term SOFR + 8.0 % $ 505,000 $ 461,877 Level 3 208 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) $ 505 million December 2024 Promissory Note (4) On December 10, 2024 in connection with an equity offering, the company and Nant Capital entered into a second amended and restated promissory note. Pursuant to the terms of the second amended and restated promissory note, Tranche 1 of the December 2023 Promissory Note with a principal amount of $ 125.0 million and Tranche 2 of the December 2023 Promissory Note with a principal amount of $ 380.0 million were combined into one convertible promissory note with a principal amount of $ 505.0 million with a maturity date of December 31, 2027. The $ 505 million December 2024 Promissory Note bears an interest rate of Term SOFR plus 8.0 % per annum, payable on a quarterly basis. Pursuant to the terms of the second amended and restated promissory note, the noteholder, in its sole discretion, may convert all of the outstanding principal amount into shares of common stock at a conversion price of $ 5.4270 per share. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. Upon receipt of a written notice of prepayment from the company, the noteholder has the option to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon into shares of the company’s common stock at the same conversion price of $ 5.4270 per share. In addition, the noteholder can request up to $ 50.0 million of the outstanding principal amount and accrued interest to be repaid upon consummation of a specified transaction. On January 23, 2026, the company entered into an amendment to the $ 505 million December 2024 Promissory Note, to grant the holder the right to convert any portion of the outstanding principal amount into shares of the company’s common stock at any time prior to the maturity date. See Note 23 “Subsequent Events—Amendment to the Second Amended and Restated Promissory Note” for more information. In connection with the RIPA transaction, the outstanding related party convertible note was subordinated to the RIPA payment obligations. Mandatory Prepayment Feature The embedded derivative related to a contingently exercisable prepayment feature, which allows the noteholder to request up to a $ 50.0 million prepayment and accrued interest upon occurrence of a specified transaction (defined in the promissory note) was recorded as a derivative liability on the consolidated balance sheet and measured at fair value prior to the second amended and restated promissory note. The fair value of the derivative liability was determined at each period end using the with-and-without method, which assessed the likelihood and timing of a specified transaction that if triggered could have resulted in a repayment. Changes in the fair value of the derivative liability were reported in change in fair value of derivative liabilities , on the consolidated statement of operations. Since the company elected the fair value option to account for the $ 505 million December 2024 Promissory Note, the embedded derivative is no longer required to be recorded separately but is considered when estimating the fair value of the $ 505 million December 2024 Promissory Note. The change in fair value of the contingently exercisable prepayment feature embedded derivative through December 10, 2024, the date of the $ 505 million December 2024 Promissory Note amendment, was $ 0.8 million. $ 300 million December 2021 Promissory Note (1), (2), (3) On December 17, 2021, the company executed a $ 300.0 million promissory note with N ant Capital, an af filiated entity under common control of our Founder, Executive Chairman and Global Chief Scientific and Medical Officer. The note bore an interest rate of Term SOFR plus 5.4 % per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest on advances were due on December 17, 2022. In the event of a default on the loan (as defined in both the original and amended and restated promissory notes), including if the company does not repay the loan at maturity, the company had the right, at its sole option, to convert the outstanding principal amount and accrued and unpaid interest due under this note into shares of the company’s common stock at a price of $ 5.67 per share. On August 31, 2022, the company and Nant Capital entered into an amended and restated promissory note, pursuant to which the maturity date of the promissory note was extended to December 31, 2023 and the interest rate was amended to Term SOFR plus 8.0 % per annum. 209 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) On September 11, 2023, the company and Nant Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December 31, 2024. On December 29, 2023 in connection with the RIPA, the company and Nant Capital entered into an amended and restated promissory note pursuant to which this existing promissory note was amended to be included in the Tranche 2 principal amount of the amended $ 505 million December 2023 promissory note, with a maturity date of December 31, 2025, and an interest rate of Term SOFR plus 7.5 % per annum. Based on the terms of the amended and restated promissory note, the noteholder, at its sole discretion, could convert all of the Tranche 2 $ 380.0 million principal amount into shares of common stock at a conversion price of $ 8.2690 per share. $ 125 million August 2022 Promissory Note (1), (2), (3) On August 31, 2022, the company executed a $ 125.0 million promissory note with Nant Capital. The note bears an interest rate of Term SOFR plus 8.0 % per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. On September 11, 2023, the company and Nant Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was extended to December 31, 2024. On December 29, 2023 in connection with the RIPA, the company and Nant Capital entered into an amended and restated promissory note letter agreement pursuant to which the existing promissory note was amended to be included in the Tranche 1 principal amount of the amended $ 505 million December 2023 promissory note, with a maturity date of December 31, 2025 and an interest rate of Term SOFR plus 8.0 % per annum. $ 50 million December 2022 Promissory Note (2), (3) On December 12, 2022, the company executed a $ 50.0 million promissory note with Nant Capital. The note bore an interest rate of Term SOFR plus 8.0 % per annum, payable on a quarterly basis. The company could prepay the outstanding promissory note, at any time, in whole or in part, without penalty. In the event of a specified transaction (as defined in the note), the noteholder could request the outstanding principal and interest due on the loan to be repaid in full upon consummation of such specified transaction. On September 11, 2023, the company and Nant Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December 31, 2024. On December 29, 2023 in connection with the RIPA, the company and Nant Capital entered into an amended and restated promissory note pursuant to which the existing promissory note was amended to be included in the Tranche 2 principal amount of the amended $ 505 million December 2023 promissory note, with a maturity date of December 31, 2025, and an interest rate of Term SOFR plus 7.5 % per annum. Pursuant to the terms of the amended and restated promissory note, the investor, in its sole discretion, could convert all of the outstanding Tranche 2 principal amount into shares of common stock at a conversion price of $ 8.2690 per share. The noteholder could request up to $ 50.0 million of the Tranche 2 principal amount and accrued interest to be repaid upon consummation of such specified transaction. $ 30 million March 2023 Promissory Note (2), (4) On March 31, 2023, the company executed a $ 30.0 million promissory note with Nant Capital. This note bore interest at Term SOFR plus 8.0 % per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest was originally due on December 31, 2023. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. Upon receipt of a written notice of prepayment from the company, the noteholder could choose to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon into shares of the company’s common stock at a price of $ 2.28 per share. Additionally, the noteholder could at its option convert the entire outstanding principal amount of the promissory note and accrued interest into shares of the company’s common stock at a conversion price of $ 2.28 per share, at the option of the noteholder. 210 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The company received net proceeds of approximately $ 29.9 million from this financing, net of a $ 0.1 million origination fee paid to the noteholder. On September 11, 2023, the company and Nant Capital entered into a letter agreement pursuant to which the maturity date of the $ 30.0 million promissory note described above was extended from December 31, 2023 to December 31, 2024. On December 29, 2023 in connection with the RIPA, the company and Nant Capital entered into a letter agreement pursuant to which the maturity date of this promissory note was extended to December 31, 2025. On December 10, 2024 in connection with an equity offering, the company received a written notice from Nant Capital, the holder of the $ 30.0 million promissory note due December 31, 2025, of its election to convert the entire outstanding principal and accrued interest under the existing note into shares of the company’s common stock. As of such date, the total outstanding principal amount and accrued and unpaid interest due under the existing note were converted into shares of the company’s common stock. See Note 17 “Stockholders’ Deficit” for more information. $ 30 million June 2023 Promissory Note (2), (3) On June 13, 2023, the company executed a $ 30.0 million promissory note with Nant Capital, pursuant to which, the company could request up to three (3) advances of $ 10.0 million each. The principal amount of each advance bore interest rate at Term SOFR plus 8.0 % per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest on advances was originally due on December 31, 2023. We could prepay the outstanding principal amount, together with any accrued interest, on any then-outstanding advances, at any time, in whole or in part, without premium or penalty, and without the prior consent of the noteholder upon five (5) days written notice to the noteholder. We received net proceeds of approximately $ 29.9 million from this promissory note, net of a $ 0.1 million origination fee paid to Nant Capital. On September 11, 2023, the company and Nant Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December 31, 2024. On December 29, 2023 in connection with the RIPA, the company and Nant Capital entered into an amended and restated promissory note pursuant to which the existing promissory note was amended to be included in the Tranche 2 principal amount of the amended $ 505 million December 2023 promissory note, with a maturity date of December 31, 2025, and an interest rate of Term SOFR plus 7.5 % per annum. Pursuant to the terms of the amended and restated promissory note the investor, in its sole discretion, could convert all of the Tranche 2 $ 380.0 million principal amount into shares of common stock at a conversion price of $ 8.2690 per share. $ 200 million September 2023 Promissory Note (2), (4) On September 11, 2023, the company executed a $ 200.0 million convertible promissory note with Nant Capital. The note bore interest at Term SOFR plus 8.0 % per annum, payable on a monthly basis. The outstanding principal amount and any accrued and unpaid interest were due on September 11, 2026. We could prepay the outstanding principal amount, together with any accrued interest, at any time, in whole or in part, without premium or penalty upon five (5) days’ written notice to the noteholder. The noteholder had the sole option to convert all (but not less than all) of the outstanding principal amount and accrued but unpaid interest into shares of the company’s common stock at a conversion price of $ 1.9350 per share. The company received net proceeds of approximately $ 199.0 million from this financing, net of a $ 1.0 million origination fee paid to the noteholder. On December 10, 2024 in connection with an equity offering, the company received a written notice from Nant Capital, the holder of the $ 200.0 million promissory note due September 11, 2026 of its election to convert the entire outstanding principal and accrued interest due under the existing note into shares of the company’s common stock. As of such date, the total outstanding principal amount and accrued and unpaid interest due under the note were converted into shares of the company’s common stock. See Note 17 “Stockholders’ Deficit” for more information. 211 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Footnotes to Related-Party Debt Debt Modification and Debt Extinguishments (1) August 2022 Debt Extinguishment On August 31, 2022, the company amended and restated the above fixed-rate notes payables held by Nant Capital, NantWorks, NantMobile and NCSC, which are entities affiliated with Dr. Soon-Shiong. Prior to the amendments and restatements, these notes bore and thereafter continued to bear interest at a per annum rate ranging from 3.0 % to 6.0 %, provided that the outstanding principal was and thereafter continued to be due and payable on September 30, 2025, and accrued and unpaid interest was or continued to be payable either upon maturity or, with respect to one of the notes, on a quarterly basis. Prior to the amendments and restatements, the company could and thereafter continued to be able to prepay the outstanding principal (together with accrued and unpaid interest), either in whole or in part, at any time without premium or penalty and without the prior consent of the noteholder, subject to an advance notice period of at least five business days during which the noteholder could convert the amount requested to be prepaid by the company into shares of the company’s common stock, as part of the amendment and restatement. The terms of these fixed-rate promissory notes were amended and restated to include a conversion feature that gave each noteholder, at its sole option, at any time (other than when the noteholder is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company’s common stock at a price of $ 5.67 per share. Since all of the above promissory notes were entered into or amended at the same time and with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. ASC 470-50 provides that a modification or an exchange that adds or eliminates a substantive conversion option as of the conversion date would always be considered substantial and require extinguishment accounting. Accordingly, as a result of the addition of the conversion feature to the fixed-rate promissory notes, the fixed-rate promissory notes and the variable-rate promissory notes were determined to be extinguished given the contemporaneous nature of the amendments. The company performed a valuation of the fixed-rate promissory notes and variable-rate promissory notes before and after amendments. Under this model, the company calculated a gain on extinguishment of $ 82.9 million, representing the difference between the fair value of the new and amended promissory notes and the carrying value of the extinguished debt, net of any unamortized related-party notes discounts plus the cash proceeds from the new promissory note. Since the debt was obtained from entities under common control, such gain was recorded in additional paid-in capital , on the consolidated statement of stockholders’ deficit during the year ended December 31, 2022. Also, the difference between the face values of the new and amended promissory notes (and accrued interest on the date of the amendment) and the fair values of the new and restated promissory notes was recorded as a debt discount to be amortized to interest expense over the remaining term (or until conversion in the case of fixed-rate promissory notes) of the respective promissory notes. During the years ended December 31, 2023 and 2022, we recorded amortization of related-party notes discounts totaling $ 42.4 million and $ 16.3 million, respectively, in interest expense , on the consolidated statement of operations. The fair values of the promissory notes without a holder conversion option were estimated using discounted cash flow analyses, based on market rates available to the company for similar debt at issuance after consideration of default and credit risk and the level of subordination. The fair values of the fixed-rate promissory notes, which were each modified to include a holder conversion option, were determined based on a binomial lattice convertible note model. The analysis involved the construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate tree. Since certain of the factors analyzed are considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be Level 3 valuations. Significant unobservable inputs used for the discounted cash flow analysis included market yields from 18.0 % to 24.8 %, and the significant unobservable inputs used for the binomial lattice model included a volatility of 84.9 %, and a market yield of 17.4 %. 212 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) On December 12, 2022, the company received written notice from NantWorks, the holder of an existing convertible promissory note of NantCell, a wholly-owned subsidiary of the company, of its election to convert the NantCell promissory note into shares of the company’s common stock. As of such date, the holder of the NantCell note converted the entire $ 56.6 million of outstanding principal and accrued and unpaid interest due under the note into 9,986,920 shares of the company’s common stock at a price of $ 5.67 per share in accordance with the terms of the promissory note. (2) September 11, 2023 Debt Modification On September 11, 2023, the company entered into a stock purchase agreement with Nant Capital, NantMobile and NCSC pursuant to which the holders exchanged promissory notes totaling approximately $ 270.0 million in aggregate principal amount and accrued unpaid interest for an aggregate of 209,291,936 shares of common stock at an exchange price of $ 1.29 per share. As a result of the exchange, the company was forever released and discharged from all its obligations and liabilities under the notes. On September 11, 2023, the company and Nant Capital entered into a series of letter agreements pursuant to which the maturity date of the related-party nonconvertible notes described above totaling $ 505.0 million in principal and the $ 30.0 million March 2023 Promissory Note was extended from December 31, 2023 to December 31, 2024. In addition, the company entered into the $ 200.0 million September 2023 promissory note with Nant Capital. No other material terms or conditions of these promissory notes were modified. Since all of the above promissory notes were entered into or amended at the same time on September 11, 2023 and with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. Pursuant to ASC 470-50, as the terms of the amendment were not substantially different than the terms of the promissory notes prior to the amendment, the amendment was accounted for as a debt modification. The unamortized debt discounts from the promissory notes are being amortized as an adjustment to interest expense over the remaining term of modified promissory notes that are not recorded at fair value using the effective interest rate method. Also, a $ 29.6 million increase in fair value of the embedded conversion feature from the debt modification was accounted for as a debt discount to the $ 200.0 million convertible note that is not recorded at fair value, and a $ 1.6 million increase in fair value of the embedded conversion feature related to the promissory note recorded at fair value was accounted for as interest expense during the year ended December 31, 2023. Such increase in fair values of the embedded conversion features totaling $ 31.2 million has been recorded with a corresponding increase in additional paid-in capital , on the consolidated statement of stockholders’ deficit. (3) December 29, 2023 Debt Extinguishment On December 29, 2023 in connection with the RIPA, the company and Nant Capital entered into an amended and restated promissory note and a letter amendment for the following outstanding promissory notes. Pursuant to the terms of the amended and restated promissory note, the amended $ 505 million December 2023 promissory note became comprised of a Tranche 1 with principal amount of $ 125.0 million which was previously the $ 125 million August 2022 promissory note before amendment, and a Tranche 2 with principal amount of $ 380.0 million, which was made up of the previous $ 300 million December 2021 promissory note, $ 50 million December 2022 promissory note and $ 30 million June 2023 promissory note. In addition, the amendment allowed Nant Capital, in its sole discretion, to convert all the Tranche 2 principal amount of $ 380.0 million of the amended promissory note into shares of common stock. The conversion price was subsequently determined at $ 8.2690 per share based on the agreement. The maturity date of the amended promissory note was December 31, 2025. Pursuant to the terms of the letter amendment, the maturity date of the $ 30 million March 2023 promissory note was extended from December 31, 2024 to December 31, 2025. Also, in connection with the RIPA transaction, all outstanding related-party promissory notes became subordinated to the RIPA payment obligations. 213 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The following table summarizes the Nant Capital promissory notes before the amendments on December 29, 2023 (principal amount in thousands): Principal Amount Maturity Year Conversion Price Interest Rate Related-Party Nonconvertible Note: $ 125 million August 2022 Promissory Note $ 125,000 2024 Term SOFR + 8.0 % Related-Party Convertible Notes: $ 300 million December 2021 Promissory Note $ 300,000 2024 Term SOFR + 8.0 % $ 50 million December 2022 Promissory Note 50,000 2024 Term SOFR + 8.0 % $ 30 million June 2023 Promissory Note 30,000 2024 Term SOFR + 8.0 % $ 30 million March 2023 Promissory Note 30,000 2024 $ 2.2800 Term SOFR + 8.0 % $ 200 million September 2023 Promissory Note 200,000 2026 $ 1.9350 Total related-party promissory notes before amendments $ 735,000 214 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The following table summarizes the Nant Capital promissory notes after the amendments on December 29, 2023 (principal amount in thousands): Principal Amount Maturity Year Conversion Price Interest Rate Related-Party Nonconvertible Note: $ 505 million December 2023 Promissory Note – Tranche 1 $ 125,000 2025 Term SOFR + 8.0 % Related-Party Convertible Notes: $ 300 million December 2021 Promissory Note $ 300,000 $ 50 million December 2022 Promissory Note 50,000 $ 30 million June 2023 Promissory Note 30,000 $ 505 million December 2023 Promissory Note – Tranche 2 380,000 2025 $ 8.2690 Term SOFR + 7.5 % Total $ 505 million December 2023 Promissory Note 505,000 $ 30 million March 2023 Promissory Note 30,000 2025 $ 2.2800 Term SOFR + 8.0 % $ 200 million September 2023 Promissory Note 200,000 2026 $ 1.9350 Term SOFR + 8.0 % Total related-party promissory notes after amendments $ 735,000 Since all of the above outstanding promissory notes were amended at the same time, with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. Also, in accordance with ASC 470-50 the company used the debt terms that existed before the September 11, 2023 modification to determine whether the modification was substantially different, as the September 11, 2023 modification was within a year of the transaction, and the promissory notes, at that time, had been modified without being deemed to be substantially different. As the modifications (September 11, 2023 and December 29, 2023 on a cumulative basis) added a substantive conversion feature to the promissory notes, these promissory notes were determined to be extinguished given the contemporaneous nature of the amendments. The company performed a valuation of all the promissory notes before and after amendments. Under this model, the company calculated a loss on extinguishment of $ 318.8 million, representing the difference between the fair value of the amended promissory notes and the carrying value of the extinguished debt, net of any unamortized related-party notes discounts. Since the debt was obtained from entities under common control, such loss was recorded in additional paid-in capital. In addition, a debt premium totaling $ 354.9 million, calculated as the difference between the fair values of certain promissory notes after modifications and their respective face values, was also recorded in additional paid-in capital. Collectively, a net gain on debt extinguishment of $ 36.1 million was recorded in additional paid-in capital, on the consolidated statement of stockholders’ deficit for the year ended December 31, 2023. Also, the difference between face values of certain new and amended promissory notes and their respective fair values of $ 53.1 million was recorded as a debt discount to be amortized as interest expense over the remaining term. During the year ended December 31, 2023, we recorded amortization of related-party notes discounts totaling $ 0.5 million in interest expense, on the consolidated statement of operations related to the new and amended promissory notes. 215 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) In regard to the Tranche 2 principal amount of the $ 505 million December 2023 promissory note, the company identified an embedded derivative related to a contingent exercisable prepayment feature of the promissory note, which allowed the noteholder to request up to a $ 50.0 million prepayment of the promissory note and accrued interest upon the occurrence of a specified transaction. After the debt extinguishment, the company concluded that this promissory note was issued at a substantial discount, so the embedded derivative that was contingently exercisable was required to be bifurcated and accounted separately from the debt host instrument. The fair value of the embedded derivative was estimated at $ 0.8 million as of December 31, 2023, using a “with-and-without” method, which assesses the likelihood and timing of the specified transaction to be triggered and result in a repayment. The estimated fair value was computed with the following unobservable inputs: As of Amendment Date December 29, 2023 Expected market yield 23.2 % Expected volatility 118.0 % The fair value of Tranche 1 principal amount of the amended $ 505 million December 2023 promissory note, which had no noteholder conversion option, was estimated using discounted cash flow analyses, based on market rates available to the company for similar debt at issuance after consideration of default and credit risk and the level of subordination. The fair value of Tranche 2 of the amended promissory note, which was modified to include a noteholder conversion option, was determined based on a binomial lattice convertible note model. The analysis involved the construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate tree. Since certain of the factors analyzed were considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be Level 3 valuations. The effective unamortized debt discount rate of the amended Tranche 1 and Tranche 2 principal amount of the $ 505 million December 2023 promissory note was 23.65 % and 18.04 %, respectively. The estimated fair value was computed with the following unobservable inputs: As of Amendment Date December 29, 2023 Expected market yield 23.2 % Expected volatility 118.0 % The fair value of the $ 200 million September 2023 promissory note was determined using the binomial lattice model with the following unobservable inputs: As of Amendment Date December 29, 2023 Expected market yield 23.3 % Expected volatility 119.3 % 216 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Prior to December 29, 2023, the $ 30 million March 2023 promissory note was accounted for under the ASC 825 FVO election. Under the FVO election, the note was initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the convertible note was computed using the binomial lattice model with the following unobservable inputs before it was modified on December 29, 2023. After the debt extinguishment, the note was accounted for under the amortized cost basis. As of Amendment Date December 29, 2023 Expected market yield 23.5 % Expected volatility 138.0 % The change in the carrying value of this note was as follows (in thousands): Fair value at issuance date, March 31, 2023 $ 29,850 Change in fair value 36,203 Gain on debt extinguishment with entities under common control ( 36,053 ) Carrying value, December 29, 2023 $ 30,000 (4) December 10, 2024 Debt Extinguishment On December 10, 2024 in connection with an equity offering, the company and Nant Capital entered into a second amended and restated promissory note. Pursuant to the terms of the second amended and restated promissory note, Tranche 1 of the December 2023 Promissory Note with a principal amount of $ 125.0 million and Tranche 2 of the December 2023 Promissory Note with a principal amount of $ 380.0 million were combined into one convertible promissory note with a principal amount of $ 505.0 million with a maturity date of December 31, 2027. The $ 505 million December 2024 Promissory Note bears an interest rate of Term SOFR plus 8.0 % per annum, payable on a quarterly basis. Pursuant to the terms of the second amended and restated promissory note, the noteholder, in its sole discretion, may convert all of the outstanding principal amount into shares of common stock at a conversion price of $ 5.4270 per share. In addition, the noteholder can request up to $ 50.0 million of the outstanding principal amount and accrued interest to be repaid upon consummation of a specified transaction. Also, on the same date, the company received a written notice from Nant Capital, the holder of the $ 30 million March 2023 Promissory Note due on December 31, 2025 and the $ 200 million September 2023 Promissory Note due on September 11, 2026 of its election to convert the entire outstanding principal and accrued interests of the such promissory notes into shares of the company’s common stock (the “Converted Promissory Notes”). As of such date, the total outstanding principal amount and accrued and unpaid interests due under the Converted Promissory Notes were converted into shares of the company’s common stock. Since the $ 505 million December 2024 Promissory Note, together with the Converted Promissory Notes, were executed contemporaneously and in contemplation with one another with entities under common control, the company evaluated these transactions collectively as a single unit of account to accurately capture the economics of the transactions. The company determined the fair value of the conversion feature before and after the above transactions to assess whether there is a substantial change in fair value. The company used binomial lattice models for the “with” scenario and discounted cash flow model for the “without” scenario. The company determined that the fair value of the conversion feature before modification is substantially different than the fair value after modification, and as such, these transactions were accounted for as debt extinguishment in accordance with ASC 470-50. Under this model, the company calculated a gain on debt extinguishment of $ 10.4 million, which represents the difference between the: (a) fair value of the December 2024 Promissory Note and the reacquisition price of the Converted Promissory Notes on the date of conversion; and (b) carrying value of the extinguished debt, net of any unamortized related party notes discounts plus, the debt premium previously recognized in additional paid-in capital , on the consolidated statement of stockholders’ deficit as a result of the December 29, 2023 Debt Extinguishment. Since the debt was obtained from entities under common control, such gain on extinguishment was recorded in additional paid-in capital , on the consolidated statement of stockholders’ deficit. 217 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Due to the conversion of the Converted Promissory Notes, the Company also recorded $ 188.5 million in additional paid-in capital , on the consolidated statement of stockholders’ deficit as of December 31, 2024. This represents the difference between the reacquisition price of the Converted Promissory Notes on the date of conversion and the debt premium previously recognized in additional paid-in capital , on the consolidated statement of stockholders’ deficit as a result of the December 29, 2023 Debt Extinguishment. See Note 17 “Stockholders’ Deficit” for more information. The estimated fair value of the Converted Promissory Notes were computed with the following unobservable inputs at the amendment date on December 10, 2024: $ 30 million March 2023 Promissory Note $ 200 million September 2023 Promissory Note Binomial lattice model: Expected market yield 18.5 % 18.6 % Expected volatility 103.2 % 118.6 % Discounted cash flow model: Discount rate 18.5 % 18.6 % The company elected the fair value option for recognizing the $ 505 million December 2024 Promissory Note under ASC 825. Under the FVO election, the note was initially measured at estimated fair value upon issuance and is remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the convertible note was computed using the following unobservable inputs at the following dates: Immediately After the Amendment on December 10, 2024 As of December 31, 2024 As of December 31, 2025 Binomial lattice model: Expected market yield 18.7 % 19.3 % 14.8 % Expected volatility 115.1 % 125.6 % 87.5 % The change in the fair value of this note was as follows (in thousands): Fair value at issuance date, December 10, 2024 $ 518,378 Interest payment ( 11,808 ) Change in fair value, including $ 1.2 million related to instrument-specific credit risk ( 44,693 ) Fair value, at December 31, 2024 461,877 Change in fair value of related-party convertible note 42,773 Change in fair value of related-party convertible note related to instrument-specific credit risk ( 27,557 ) Fair value, at December 31, 2025 $ 477,093 During the years ended December 31, 2025 and 2024, the company recorded gains of $ 27.6 million and $ 1.2 million, respectively, in change in fair value of related-party convertible note related to instrument-specific credit risk, on the consolidated statements of comprehensive loss. 218 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The following tables summarize the interest expense for our related-party promissory notes during the years ended December 31, 2025, 2024 and 2023 (in thousands): Year Ended December 31, 2025 Interest Expense Debt Discount Amortization $ 505 million December 2024 Promissory Note $ 60,886 $ — Total $ 60,886 $ — Year Ended December 31, 2024 Interest Expense Debt Discount Amortization $ 505 million December 2024 Promissory Note $ 3,585 $ — $ 505 million December 2023 Promissory Note Tranche 1 15,281 8,454 $ 505 million December 2023 Promissory Note Tranche 2 44,658 14,133 $ 30 million March 2023 Promissory Note 3,667 — $ 200 million September 2023 Promissory Note 24,810 — Total $ 92,001 $ 22,587 Year Ended December 31, 2023 Interest Expense Debt Discount Amortization $ 300 million December 2021 Promissory Note (1) $ 39,653 $ 27,967 $ 125 million August 2022 Promissory Note (1) 16,521 5,962 $ 50 million December 2022 Promissory Note (1) 6,609 478 $ 30 million March 2023 Promissory Note (1) 4,590 — $ 30 million June 2023 Promissory Note 2,096 258 $ 200 million September 2023 Promissory Note 8,185 2,586 Related-Party Fixed-Rate Promissory Notes 8,799 5,145 Total $ 86,453 $ 42,396 _______________ (1) Balances include the amortization of debt discount totaling $ 0.5 million recorded during the period from December 29, 2023 to December 31, 2023. The interest expense recorded during this period was $ 0.4 million. 219 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The following table summarizes the estimated future contractual obligations of our related-party debt as of December 31, 2025 (in thousands): Principal Payments Interest Payments (1) Total 2026 $ — $ 58,887 $ 58,887 2027 505,000 58,887 563,887 Total $ 505,000 $ 117,774 $ 622,774 _______________ (1) Interest payments on our promissory note are calculated based on Term SOFR plus the contractual spread per the loan agreement. The interest rate on our promissory note as of December 31, 2025 was 11.66 %. Interest expense consists of the following (in thousands): Year Ended December 31, 2025 2024 2023 Interest expense on related-party notes payable $ 60,886 $ 92,001 $ 86,453 Amortization of related-party notes discounts — 22,587 42,396 Interest expense – related party $ 60,886 $ 114,588 $ 128,849 In connection with the RIPA transaction, the outstanding related-party convertible note was subordinated to the RIPA payment obligations. 15. Related-Party Agreements Our Founder, Executive Chairman and Global Chief Scientific and Medical Officer also founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new immunotherapies for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Founder, Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder. NantWorks, LLC Shared Services Agreement Under the amended and restated shared services agreement with NantWorks dated as of June 2016, but effective as of August 2015, NantWorks, a related party, provides corporate, general and administrative, certain research and development, and other support services to us, and we provide certain of such services to them. The receiving party is charged for the services at cost plus reasonable allocations of employee benefits, facilities, and other direct or fairly allocated indirect costs that relate to the employees providing the services. During the years ended December 31, 2025, 2024 and 2023, we recorded $ 2.1 million, $ 2.6 million and $ 3.3 million, respectively, in selling, general and administrative – related parties , and $ 0.8 million, $ 3.3 million, and $ 2.2 million, respectively, of expense reimbursements under this arrangement in research and development – related parties, on the consolidated statements of operations. These amounts exclude certain immaterial general and administrative expenses provided by third-party vendors directly for our benefit, which were reimbursed to NantWorks based on those vendors’ invoiced amounts without markup by NantWorks. 220 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) As of December 31, 2025 and 2024, we had a payable of $ 0.2 million and a receivable of $ 0.2 million, respectively, for all agreements with NantWorks, which are included in due to/due from related parties, on the consolidated balance sheets. We also recorded $ 0.7 million and $ 3.0 million of prepaid expenses for various services that we expect will be passed through to the company from NantWorks as of December 31, 2025 and 2024, respectively, which are included in prepaid expenses – related parties , on the consolidated balance sheets. Facility License Agreement In 2015, we entered into a facility license agreement with NantWorks for office space in Culver City, California, which was converted to a research and development laboratory and a cGMP manufacturing facility. During the years ended December 31, 2025, 2024 and 2023, we recorded license fee expense for this facility totaling $ 3.6 million, $ 3.5 million, and $ 3.4 million, respectively, in research and development – related parties , on the consolidated statements of operations. Related-Party Leases The company leases certain assets under operating leases with certain entities controlled by NantWorks and its affiliates or subsidiaries. Right-of-use assets for related-party operating leases totaled $ 13.2 million and $ 16.0 million, and the associated operating lease liabilities totaled $ 17.0 million and $ 20.4 million, as of December 31, 2025 and 2024, respectively. The company recorded operating lease expense totaling $ 4.6 million, $ 4.6 million and $ 4.5 million for the years ended December 31, 2025, 2024 and 2023, respectively. Related-party leases were classified as either selling, general and administrative – related parties or research and development – related parties , on the consolidated statements of operations, depending on the use of the facility. Immuno-Oncology Clinic, Inc. We have entered into multiple agreements with t he Clinic to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. During the years ended December 31, 2025, 2024 and 2023, we recorded $ 2.9 million, $ 2.6 million, and $ 2.2 million respectively, related to clinical trial and transition services provided by the Clinic in research and development – related parties , on the consolidated statements of operations. As of December 31, 2025 and 2024, we owed the Clinic a $ 0.1 million and an immaterial amount, respectively, which are included in due to related parties , on the consolidated balance sheets. 16. Warrant Liabilities The company issued warrants through RDOs. In the event of certain fundamental transactions involving the company, the holders of the warrants may require the company to make a payment based on a Black-Scholes valuation, using specified inputs that are not considered indexed to the company’s stock in accordance with ASC 815. Therefore, we classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The proceeds from issuance of common stock and warrants are allocated to warrants based on its fair value. The warrants issued by the company are summarized below: December 2022 Warrants In connection with the December 12, 2022 RDO, the company issued 9,090,909 warrants with an exercise price of $ 6.60 per share. The warrants became immediately exercisable on December 12, 2022 and expired in full on December 12, 2024. February 2023 Warrants In connection with the February 15, 2023 RDO, the company issued 14,072,615 warrants with an exercise price of $ 4.2636 per share. The warrants became immediately exercisable on February 17, 2023 and expire two years after the initial issuance date. On July 25, 2023, the company amended the terms of the warrant, reducing the exercise price of the warrants from $ 4.2636 per share to $ 3.2946 per share and extending the expiration date of the warrants until July 24, 2026. The fair value of warrants was estimated at $ 23.7 million at the issuance date. Of the total offering costs, $ 1.0 million were allocated to the warrants and recorded in other income (expense), net , on the consolidated statement of operations on the date of the transaction . Since the warrants were classified as liabilities and measured at fair value, we recognized the change of $ 7.3 million in fair value of warrant liability in earnings due to the warrant modification. 221 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) July 2023 Warrants In connection with the July 20, 2023 RDO, the company issued 14,569,296 warrants with an exercise price of $ 3.2946 per share. These warrants became immediately exercisable on July 25, 2023 and expire on July 24, 2026. The fair value of warrants was estimated at $ 25.8 million at the issuance date. Of the total offering costs, $ 1.0 million were allocated to the warrants and recorded in other income (expense), net , on the consolidated statement of operations on the date of the transaction . April 2025 Warrants In connection with the April 7, 2025 RDO, the company issued 29,024,768 warrants with an exercise price of $ 3.1010 per share. These warrants became immediately exercisable on April 9, 2025 and expire on April 9, 2030. The fair value of warrants was estimated at $ 61.8 million at the issuance date. Of the total offering costs, $ 0.1 million were allocated to the warrants and recorded in other income (expense), net , on the consolidated statement of operations on the date of the transaction. July 2025 Warrants In connection with the July 24, 2025 RDO, the company issued 29,629,632 warrants with an exercise price of $ 3.240 per share. These warrants became immediately exercisable on July 28, 2025 and expire on July 28, 2030. The fair value of warrants was estimated at $ 63.1 million at the issuance date. Of the total offering costs, $ 2.0 million were allocated to the warrants and recorded in other income (expense), net , on the consolidated statement of operations on the date of the transaction. Warrant Liabilities The following table summarizes the change in carrying amount of warrant liabilities measured at fair value during the years ended December 31, 2025, 2024, and 2023 (in thousands): Total December 2022 Warrants February 2023 Warrants July 2023 Warrants April 2025 Warrants July 2025 Warrants Fair value, at December 31, 2022 $ 21,636 $ 21,636 $ — $ — $ — $ — Fair value at issuance 49,534 — 23,698 25,836 — — Change in fair value 47,600 ( 4,545 ) 26,260 25,885 — — Fair value, at December 31, 2023 118,770 17,091 49,958 51,721 — — Warrant exercises ( 90,240 ) — ( 46,083 ) ( 44,157 ) — — Change in fair value ( 19,955 ) ( 17,091 ) ( 103 ) ( 2,761 ) — — Fair value, at December 31, 2024 8,575 — 3,772 4,803 — — Fair value at issuance 124,931 — — — 61,823 63,108 Change in fair value ( 49,089 ) — ( 3,542 ) ( 4,510 ) ( 20,347 ) ( 20,690 ) Fair value, at December 31, 2025 $ 84,417 $ — $ 230 $ 293 $ 41,476 $ 42,418 222 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Warrant Exercises The following table summarizes warrant exercise activity during the years ended December 31, 2025, 2024, and 2023: Total December 2022 Warrants February 2023 Warrants July 2023 Warrants April 2025 Warrants July 2025 Warrants Warrants outstanding, at December 31, 2022 9,090,909 9,090,909 — — — — Warrant exercises — — — — — — Warrant issuances 28,641,911 — 14,072,615 14,569,296 — — Warrants outstanding, at December 31, 2023 37,732,820 9,090,909 14,072,615 14,569,296 — — Warrant exercises ( 22,242,740 ) — ( 11,258,092 ) ( 10,984,648 ) — — Warrant expirations ( 9,090,909 ) ( 9,090,909 ) — — — — Warrants outstanding, at December 31, 2024 6,399,171 — 2,814,523 3,584,648 — — Warrant exercises — — — — — — Warrant issuances 58,654,400 — — — 29,024,768 29,629,632 Warrants outstanding, at December 31, 2025 65,053,571 — 2,814,523 3,584,648 29,024,768 29,629,632 Warrant Valuation Assumptions The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following key assumptions at the following dates: December 2022 Warrants February and July 2023 Warrants December 31, 2023 December 31, 2025 December 31, 2024 December 31, 2023 Exercise price per share $ 6.60 $ 3.2946 $ 3.2946 $ 3.2946 Expected term 1.0 years 0.6 years 1.6 years 2.6 years Expected average volatility 119.0 % 60.9 % 125.0 % 107.3 % Expected dividend yield — — — — Risk-free interest rate 4.7 % 3.5 % 4.2 % 4.1 % April 2025 Warrants July 2025 Warrants December 31, 2025 Issuance Date April 9, 2025 December 31, 2025 Issuance Date July 28, 2025 Exercise price per share $ 3.101 $ 3.101 $ 3.240 $ 3.240 Expected term 4.3 years 5.0 years 4.6 years 5.0 years Expected average volatility 113.5 % 119.1 % 110.7 % 115.9 % Expected dividend yield — — — — Risk-free interest rate 3.6 % 4.0 % 3.7 % 3.9 % 223 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The expected term is the time remaining until the expiration of the warrants. The expected average volatility was estimated based on the historical and implied volatility of our common stock. The expected dividend yield was based on our expectation of not paying dividends for the foreseeable future. The risk-free interest rate was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The significant unobservable inputs used in the warrant valuation are the expected term and the expected average volatility. 17. Stockholders’ Deficit Stock Authorized for Issuance As of December 31, 2025, the company was authorized to issue up to 1,650,000,000 shares of its common stock, par value $ 0.0001 per share, and 20,000,000 shares of our preferred stock, par value $ 0.0001 per share. As of December 31, 2025, there were 1,011,800,008 shares of our common stock outstanding (excluding 163,800 shares held by a majority-owned subsidiary of the company that are treated as treasury shares for accounting purposes). On October 20, 2025, ImmunityBio, Inc. filed a DEF 14C with the SEC to inform its stockholders of an action taken by its Board of Directors and by the written consent of stockholders representing a majority of the voting power of its common stock to amend its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 1.350 billion shares of common stock, $ 0.0001 par value per share, to 1.650 billion shares of common stock, $ 0.0001 par value per share. The number of shares of preferred stock, $ 0.0001 par value per share, that the company is authorized to issue remains unchanged at 20.0 million shares. The amendment became effective on November 10, 2025. Stock Repurchases In 2015, the Board of Directors approved the 2015 Share Repurchase Program, which allows our CEO or CFO to repurchase on behalf of the company, from time to time in the open market or in privately negotiated transactions, up to $ 50.0 million of our outstanding shares of common stock, exclusive of any commissions, markups, or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements, and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified, or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. Shares repurchased under this program are formally retired through approval of the Board of Directors upon repurchase. During the years ended December 31, 2025, 2024 and 2023, no shares of our common stock were repurchased under the program. Since the program’s inception, we have repurchased a total of 6,403,489 shares at a total cost of $ 31.7 million. As of December 31, 2025, $ 18.3 million remained authorized to use for share repurchases under the program. Shelf Registration Statements In 2023, we filed a $ 750.0 million shelf registration statement with the SEC on Form S-3 for the offering and sale of equity and equity-linked securities, including common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock or debt securities, subscription rights, purchase contracts, and units. During the year ended December 31, 2023, we sold shares our common stock and warrants valued at $ 184.4 million under this shelf. As of December 31, 2025, we had $ 565.6 million available for use under this shelf. This shelf registration statement expired on February 9, 2026. In 2024, we filed a shelf registration statement with the SEC on Form S-3ASR pursuant to which we may, from time to time, sell an indeterminate amount of our common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts, or units, and an associated prospectus related to the ATM. During the years ended December 31, 2025 and 2024, we sold 58,654,400 shares and 38,333,334 shares of our common stock, respectively, under this shelf generating net proceeds of approximately $ 150.1 million and $ 106.9 million, respectively. 224 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Open Market Sale Agreement In 2021, we entered into the ATM under which we may offer and sell, from time to time at our sole discretion, shares of our common stock through our sales agent. We pay our sales agent a commission of up to 3.0 % of the gross sales proceeds of any shares of our common stock sold through them under the ATM and also have provided them with customary indemnification and contribution rights. In December 2025, we filed a prospectus supplement to our shelf registration statement that amended the 2021 ATM agreement to increase the amount available for future stock issuances under the ATM to $ 500.0 million. During the years ended December 31, 2025, 2024 and 2023, we received net proceeds of approximately $ 250.1 million, $ 3.6 million, and $ 16.1 million, respectively, from the issuance of shares under the ATM. We are not obligated to sell any shares and may at any time suspend solicitation and offers under the ATM. The ATM may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances and shall automatically terminate upon the issuance and sale of all of the shares. Registered Direct Offerings 2025 Offerings April 2025 On April 7, 2025, we entered into a securities purchase agreement with an institutional investor for the purchase and sale of 29,024,768 shares of our common stock, as well as warrants that allows such investor to purchase an additional 29,024,768 shares of common stock at an exercise price of $ 3.1010 per share, for a purchase price of $ 2.5840 per share and accompanying warrant. This transaction generated net proceeds of approximately $ 74.8 million, after deducting offering costs of $ 0.2 million, of which $ 0.1 million was allocated to the sale of our common stock and recorded in additional paid-in capital , on the consolidated statement of stockholders’ deficit during the year ended December 31, 2025. July 2025 On July 24, 2025, we entered into a securities purchase agreement with institutional investors for the purchase and sale of 29,629,632 shares of our common stock, as well as warrants that allows such investors to purchase an additional 29,629,632 shares of common stock at an exercise price of $ 3.240 per share, for a purchase price of $ 2.700 per share and accompanying warrant. This transaction generated net proceeds of approximately $ 75.4 million, after deducting placement agent fees and offering costs totaling $ 4.6 million, of which $ 2.6 million was allocated to the sale of our common stock and recorded in additional paid-in capital , on the consolidated statement of stockholders’ deficit during the year ended December 31, 2025. 2023 Offerings February 2023 On February 15, 2023, we entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 14,072,615 shares of our common stock, as well as warrants that allow such investors to purchase an additional 14,072,615 shares of common stock at an exercise price of $ 4.2636 per share, for a purchase price of $ 3.5530 per share and accompanying warrant. This transaction generated net proceeds of approximately $ 47.0 million, after deducting placement agent fees and other offering costs of $ 3.0 million, of which $ 2.0 million was allocated to the sale of our common stock and recorded in additional paid-in capital, on the consolidated statement of stockholders’ deficit during the year ended December 31, 2023. On July 25, 2023, pursuant to the terms of a letter amendment, the company and the investors agreed to reduce the exercise price of the outstanding February 2023 Warrants from $ 4.2636 per share to $ 3.2946 per share and extend the expiration date of the warrants to July 24, 2026. See Note 16 “Warrant Liabilities” for more information. 225 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) July 2023 On July 20, 2023, we entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 14,569,296 shares of our common stock, as well as warrants that allow such investors to purchase an additional 14,569,296 shares of common stock at an exercise price of $ 3.2946 per share, for a purchase price of $ 2.7455 per share and accompanying warrant. This transaction generated net proceeds of approximately $ 37.5 million, after deducting placement agent fees and other estimated offering costs of $ 2.5 million, of which $ 12.7 million was allocated to the sale of our common stock and recorded in additional paid-in capital , on the consolidated statement of stockholders’ deficit during the year ended December 31, 2023. Warrant Exercises During the year ended December 31, 2024, institutional holders exercised a total of 11,258,092 warrants pursuant to the February 2023 Warrant agreement at an exercise price of $ 3.2946 per share resulting in the issuance of 11,258,092 shares of the company’s common stock for proceeds totaling $ 37.1 million. We recorded $ 83.2 million in additional paid-in capital, on the consolidated statement of stockholders’ deficit during the year ended December 31, 2024 related to these warrant exercises. During the year ended December 31, 2024, institutional holders exercised a total of 10,984,648 warrants pursuant to the July 2023 Warrant agreement at an exercise price of $ 3.2946 per share resulting in the issuance of 10,984,648 shares of the company’s common stock for proceeds totaling $ 36.2 million. We recorded $ 80.3 million in additional paid-in capital, on the consolidated statement of stockholders’ deficit during the year ended December 31, 2024 related to these warrant exercises. During the year ended December 31, 2025 and 2023, there were no warrant exercises pursuant to the 2025 and 2023 warrant agreements. Stock Purchase and Option Agreement On December 29, 2023 and in connection with the RIPA, we entered into a SPOA with Oberland. Under this agreement, Oberland had an option to purchase up to $ 10.0 million of our common stock, at a price per share to be determined by reference to the 30-day trailing volume weighted-average price of our common stock, calculated from the date of exercise. The option is exercisable by Oberland any time until the earliest of (i) December 29, 2028, (ii) a change of control of the company, or (iii) a sale of substantially all of the company’s assets. Among other limitations, the option may only be exercised to the extent that the common stock issuable pursuant to such exercise would not exceed 19.9 % of the common stock outstanding immediately after giving effect to such exercise. As of December 31, 2025, approximately $ 5.0 million remains available for future exercise under the SPOA. Conversion of Promissory Notes into Common Stock In connection with our December 2024 equity offering, the company received written notice from Nant Capital, the holder of the $ 30.0 million promissory note due December 31, 2025, of its election to convert the entire outstanding principal and accrued interest under the existing note into shares of the company’s common stock. As of such date, the total outstanding principal amount and accrued and unpaid interest due under the existing note of approximately $ 30.7 million were converted into 13,475,172 shares of the company’s common stock at a price of $ 2.28 per share in accordance with the terms of the promissory note. We recorded a net increase of $ 26.2 million in additional paid-in capital , on the consolidated balance sheet related to this transaction. See Note 14 “Related-Party Debt” for more information. Also, in connection with our December 2024 equity offering, the company received written notice from Nant Capital, the holder of the $ 200.0 million promissory note due September 11, 2026, of its election to convert the entire outstanding principal and accrued interest under the existing note into shares of the company’s common stock. As of such date, the total outstanding principal amount and accrued and unpaid interest due under the existing note of approximately $ 200.7 million were converted into 103,710,088 shares of the company’s common stock at a price of $ 1.9350 per share in accordance with the terms of the promissory note. We recorded a net increase of $ 162.3 million in additional paid-in capital , on the consolidated balance sheet related to this transaction. See Note 14 “Related-Party Debt” for more information. 226 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) On September 11, 2023, the company entered into a stock purchase agreement with Nant Capital, NantMobile and NCSC pursuant to which the related-party purchasers exchanged all such fixed-rate promissory notes, representing approximately $ 270.0 million in aggregate principal amount and accrued and unpaid interest, in exchange for an aggregate of 209,291,936 shares of common stock at an exchange price of $ 1.29 per share. On December 12, 2022, the company received written notice from NantWorks, the holder of the existing note, of its election to convert the entire outstanding principal and accrued and unpaid interest under the existing note into shares of the company’s common stock. As of such date, the entire outstanding principal amount and accrued and unpaid interest due under the existing note of approximately $ 56.6 million and an unamortized debt discount of $ 4.7 million were converted into 9,986,920 shares of the company’s common stock at a price of $ 5.67 per share in accordance with the terms of the existing note. We recorded a net increase of $ 51.9 million in additional paid-in capital, on the consolidated balance sheet related to this transaction. 18. Stock-Based Compensation 2025 Equity Incentive Plan On June 18, 2025, our stockholders voted to approve the 2025 Plan, which replaced the 2015 Plan in its entirety. No further awards will be made under the 2015 Plan, but the 2015 Plan will continue to govern awards previously granted under it. The 2025 Plan permits the grant of incentive stock options, within the meaning of Section 422 of the Code, to the company’s employees and the grant of non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, and Performance Awards (as defined in the 2025 Plan) to the company’s employees, directors and consultants. A total of 46,088,027 shares were reserved for issuance pursuant to the 2025 Plan. In addition, the shares reserved for issuance under the 2025 Plan also included shares subject to stock options or similar awards granted under the 2015 Plan that expire or terminate without having been exercised in full and shares issued pursuant to awards granted under the 2015 Plan that are forfeited to or repurchased by the company (provided that the maximum number of shares that may be added to the 2025 Plan pursuant to this provision is 32,359,674 shares). As of December 31, 2025, approximately 47,341,842 shares were available for future grants under the 2025 Plan. Stock-Based Compensation The following table presents stock-based compensation included on the consolidated statements of operations (in thousands): Year Ended December 31, 2025 2024 2023 Stock-based compensation expense: Stock options $ 20,284 $ 15,679 $ 13,884 RSUs 16,525 18,753 35,279 $ 36,809 $ 34,432 $ 49,163 Stock-based compensation expense in operating expenses: Research and development $ 10,620 $ 12,005 $ 17,341 Selling, general and administrative 26,189 22,427 31,822 $ 36,809 $ 34,432 $ 49,163 Stock-based compensation expense capitalized into inventory totaled $ 0.6 million for the year ended December 31, 2025. There was no stock-based compensation expense capitalized into inventory for the years ended December 31, 2024 and 2023. Capitalized stock-based compensation is recognized as an expense in cost of sales when the related product is sold. 227 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Stock Options The following table summarizes stock option activity and related information for the year ended December 31, 2025: Number of Options Weighted- Average Exercise Price Aggregate Intrinsic Value (in thousands) Weighted- Average Remaining Contractual Life (in years) Outstanding at December 31, 2024 15,407,588 $ 8.00 $ 90 7.1 Granted 11,216,448 $ 3.34 Exercised ( 110,020 ) $ 2.00 Forfeited/expired ( 2,581,512 ) $ 16.05 Outstanding at December 31, 2025 23,932,504 $ 4.97 $ 17 7.9 Vested and exercisable at December 31, 2025 9,657,097 $ 6.70 $ 17 6.3 As of December 31, 2025, the unrecognized compensation cost related to outstanding stock options was $ 30.8 million, which is expected to be recognized over a remaining weighted-average period of 1.8 years. During the years ended December 31, 2025, 2024 and 2023, the total intrinsic value of stock options exercised was $ 0.1 million, $ 0.9 million, and $ 0.3 million, respectively. During the years ended December 31, 2025, 2024 and 2023, cash proceeds received from stock option exercises were $ 0.2 million, $ 0.7 million, and $ 0.3 million, respectively. As of December 31, 2024, a total of 8,038,537 vested and exercisable stock options were outstanding. The fair value of stock options issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions: Years Ended December 31, 2025 2024 2023 Expected term 5.96 years 5.96 years 5.50 years Risk-free interest rate 4.3 % 4.3 % 4.0 % Expected volatility 120.4 % 116.8 % 116.2 % Dividend yield — % — % — % Weighted-average grant date fair value $ 2.92 $ 4.58 $ 2.53 The expected term was estimated using the average of the contractual term and the weighted-average vesting term of the options. The risk-free interest rate was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The expected volatility was estimated based on the historical volatility of our common stock. The assumed dividend yield was based on our expectation of not paying dividends for the foreseeable future. 228 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Restricted Stock Units The following table summarizes RSU activity during the year ended December 31, 2025: Number of Units Weighted- Average Grant Date Fair Value Nonvested balance at December 31, 2024 5,945,421 $ 11.41 Granted 4,875,232 $ 3.27 Vested ( 2,153,485 ) $ 12.26 Forfeited/canceled ( 539,500 ) $ 7.49 Nonvested balance at December 31, 2025 8,127,668 $ 6.56 As of December 31, 2025, there was $ 22.5 million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 1.8 years. During the years ended December 31, 2025, 2024 and 2023, the total fair value of RSUs vested was $ 5.9 million, $ 14.6 million, and $ 11.1 million, respectively. Related-Party Warrants A total of 1,638,000 warrants issued to an affiliate of Dr. Soon-Shiong with an exercise price of $ 3.240 per share were outstanding as of December 31, 2025 and 2024. The fair value of $ 18.0 million assigned to the warrants will be recognized in equity upon achievement of a performance-based vesting condition pertaining to building manufacturing capacity to support supply requirements for ANKTIVA (which has not yet been satisfied). The warrants become exercisable 30 days following the achievement of the performance-based vesting condition (the initial exercise date) and expire on the 10th anniversary of the initial exercise date. 19. Income Taxes We are subject to U.S. federal income tax, as well as income tax in California, other states, and other certain foreign jurisdictions. Except for state franchise taxes, the company has not been required to pay significant U.S. federal and state income taxes because of current and accumulated NOLs. Our federal returns for tax years 2022 through 2024 remain open to examination, and our state returns remain subject to examination for tax years 2021 through 2024. NOL carryforwards and tax credits are still subject to examination in the year they are used. No income tax returns are currently under examination by taxing authorities. There are no cumulative earnings in our foreign subsidiaries as of December 31, 2025 that would be subject to U.S. income tax or foreign withholding tax. We plan to indefinitely reinvest any future earnings of our foreign subsidiaries. Our loss before income taxes is as follows (in thousands): Year Ended December 31, 2025 2024 2023 U.S. loss before income taxes $ ( 348,393 ) $ ( 410,458 ) $ ( 581,136 ) Foreign loss before income taxes ( 3,214 ) ( 3,187 ) ( 2,756 ) Loss before income taxes $ ( 351,607 ) $ ( 413,645 ) $ ( 583,892 ) 229 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Income tax (expense) benefit consists of the following (in thousands): Year Ended December 31, 2025 2024 2023 Current: Federal $ — $ — $ — State ( 4 ) — 26 Foreign — — — Total current ( 4 ) — 26 Deferred: Federal 111 — 5 State 28 — 9 Foreign — — — Total deferred 139 — 14 Total income tax benefit $ 135 $ — $ 40 The effective income tax rate for the year ended December 31, 2025 differs from the statutory federal income tax rate presented after the adoption of ASU 2023-09 as follows (in thousands, except percentages): Year Ended December 31, 2025 $ % Provision for income taxes at U.S. federal statutory rate $ 73,838 21.0 % State and local income taxes, net of federal benefit ( 98 ) ( 0.0 )% Foreign tax effects ( 677 ) ( 0.2 ) % Effect of changes in tax laws or rates enacted in the current period — — % Tax credits: Research and development credits 4,020 1.1 % Non-taxable or non-deductible items: Equity compensation ( 10,428 ) ( 3.0 ) % Change in fair value of warrants 10,309 2.9 % Change in fair value of related-party convertible note ( 8,982 ) ( 2.6 ) % Other permanent differences ( 526 ) ( 0.2 ) % Valuation allowance ( 66,561 ) ( 18.7 ) % Uncertain tax positions ( 285 ) ( 0.1 ) % Other adjustments: Other ( 475 ) ( 0.2 ) % Total tax benefit and effective tax rate $ 135 — % 230 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) As previously disclosed prior to the adoption of ASU 2023-09 (See Note 2 “Summary of Significant Accounting Policies—Recent Accounting Pronouncements” ), the effective income tax rate differed from the statutory federal income tax rate as follows: Year Ended December 31, 2024 2023 Federal statutory tax rate 21.0 % 21.0 % State income taxes, net of federal tax benefit 5.2 % 6.8 % Change in fair value of warrants 1.0 % ( 1.8 ) % Change in fair value of convertible notes 2.2 % ( 1.3 ) % Investment loss — % 2.1 % Tax rate adjustment 3.9 % 1.4 % Research and development credits 2.5 % 3.1 % Stock-based compensation ( 1.1 ) % ( 1.0 ) % Section 162(m) limitation ( 0.5 ) % ( 0.4 ) % Other ( 4.5 ) % 0.3 % Valuation allowance ( 29.7 ) % ( 30.2 ) % Effective income tax rate — % — % The components that comprise our net deferred tax liabilities consist of the following (in thousands): As of December 31, 2025 2024 Deferred tax assets: Net operating loss carryforwards $ 567,406 $ 475,130 Section 174 R&E capitalization 80,058 111,598 Interest expense 93,311 69,681 Research and development credits 74,485 68,070 Stock-based compensation 16,760 20,799 Operating lease liabilities 10,549 10,886 Valuation discount 4,994 6,641 Other 24,630 32,604 Total deferred tax assets 872,193 795,409 Deferred tax liabilities: Debt discount ( 7,851 ) ( 9,735 ) Operating lease right-of-use assets ( 8,497 ) ( 8,589 ) Indefinite-lived intangible assets — ( 139 ) Total deferred tax liabilities ( 16,348 ) ( 18,463 ) Net deferred tax assets 855,845 776,946 Valuation allowance ( 855,845 ) ( 777,085 ) Net deferred tax liabilities $ — $ ( 139 ) 231 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Changes in our valuation allowance are as follows (in thousands): Year Ended December 31, 2025 2024 Valuation allowance – beginning of year $ 777,085 $ 648,444 Allowance taken or written off 78,162 122,845 Other adjustment – accumulated paid-in capital — 6,365 Other adjustment – other comprehensive income (loss) 598 ( 569 ) Valuation allowance – end of year $ 855,845 $ 777,085 As of December 31, 2025, we have federal NOLs of $ 2.1 billion, state NOLs of $ 2.3 billion, and foreign NOLs of $ 22.0 million. Of the $ 2.1 billion in federal NOLs, $ 1.7 billion do not expire and will be able to be used to offset 80% of taxable income in future years. Of the $ 2.3 billion in state NOLs, $ 76.3 million do not expire and will be able to be used to offset 80% of taxable income in future years. The remaining federal NOL carryforwards expire beginning in 2026, the remaining state NOL carryforwards expire beginning in 2028, the foreign NOL carryforwards expire beginning in 2026. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some or all of our deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the level of historical operating results and the uncertainty of economic conditions, we recorded a valuation allowance of $ 855.8 million and $ 777.1 million as of December 31, 2025 and 2024, respectively. During the years ended December 31, 2025 and 2024, the valuation allowance increased by $ 78.7 million and $ 128.7 million, respectively, which was mainly driven by losses from which we cannot benefit. The portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits will be credited directly to contributed capital is $ 0.2 million. The company’s valuation allowance as of December 31, 2025 increased compared to December 31, 2024 primarily due to losses from which the company cannot benefit. Pursuant to Sections 382 and 383 of the Code, annual use of our net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. We have not recognized the deferred tax assets for federal and state NOLs and credits of $ 267.5 million from our deferred tax asset schedules as of December 31, 2025 due to Section 382/383 limitations. There is no impact to tax expense for the derecognition of net operating losses, and federal and state research and development credits due to the valuation allowance recorded against our deferred tax assets. As of December 31, 2025, we also had federal research tax credit carryforwards of $ 59.6 million and state research tax credits of $ 39.7 million. The federal research tax credit carryforwards expire beginning in 2032 and certain state research tax credit carryforwards expire beginning in 2030. Our California research tax credits can be carried forward indefinitely. As of December 31, 2025, we also had federal other tax credits carryforwards of $ 1.3 million and the tax credit carryforwards expire beginning in 2036. Net operating losses and tax credits are also limited when there is a SRLY. These rules generally limit the use of the acquired or departing members’ net operating loss and tax credit carryovers to the amount of taxable income such entity contributes to consolidated taxable income. The 80% limitation also applies to SRLY NOL carryovers and tax credits. Therefore, any SRLY NOLs and tax credits will be subject to this limitation, as well as Section 382 and 383 limitations. 232 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) As of December 31, 2025 and 2024, we have $ 389.4 million and $ 287.5 million of interest, respectively, that is temporarily disallowed pursuant to Section 163(j) of the Code. This interest can be carried forward indefinitely and will be deductible when the company generates sufficient adjusted taxable income. The table below provides the updated requirements of ASU 2023-09 for 2025. See Note 2 “Summary of Significant Accounting Policies” for additional details on the adoption of ASU 2023-09. A summary of changes to the amount of unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2025 2024 2023 Unrecognized tax benefits, beginning of year $ 34,543 $ 35,470 $ 16,252 Additions based on tax positions related to the current year 1,048 1,251 18,976 Additions based on tax positions related to prior years — — 242 Reductions for tax positions of prior years ( 15,255 ) ( 2,178 ) — Unrecognized tax benefits, end of year $ 20,336 $ 34,543 $ 35,470 Included in the balance of unrecognized tax benefits as of December 31, 2025 is $ 17.0 million that, if recognized, would not impact our income tax benefit or effective tax rate as long as the deferred tax asset remains subject to a full valuation allowance. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact our effective tax rate. We have not incurred any material interest or penalties as of the current reporting date with respect to income tax matters. The company files income tax returns in the U.S., California, other states, and foreign jurisdictions. Due to the company’s losses incurred, the company is essentially subject to income tax examination by tax authorities from inception to date. The company’s policy is to recognize interest expense and penalties related to income tax matters as tax expense. As of December 31, 2025, there are no significant accruals for interest related to unrecognized tax benefits or tax penalties. Upon the prospective adoption of ASU 2023-09 we are required to disclose income taxes paid, net of refunds for 2025. All amounts for federal, state and foreign are zero for the year ended December 31, 2025. One Big Beautiful Bill Act On July 4, 2025, the OBBB Act was enacted in the U.S. The OBBB Act includes significant provisions, such as the permanent extension of certain expiring provisions of the TCJA, modifications to the international tax framework, and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The company has evaluated the OBBB Act and estimated the impact to the consolidated financial statements will not be adverse. We will continue to evaluate the full impact of these legislative changes as additional guidance becomes available. 20. Employee Benefits Defined Contribution Plan In December 2015, we adopted a 401(k) Plan covering all employees. The 401(k) Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the IRS. The company, at its discretion, may make certain contributions to the 401(k) Plan. During the years ended December 31, 2025, 2024 and 2023, we made contributions totaling $ 3.0 million, $ 3.0 million, and $ 2.8 million, respectively, to the 401(k) Plan. Compensated Absences Under our vacation policy, salaried employees are provided unlimited vacation leave. Therefore, we do not record an accrual for paid leave related to these employees since we are unable to reasonably estimate the compensated absences that these employees will take. 233 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) 21. Earnings Per Share Basic and Diluted Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The following table reflects the calculation of basic and diluted loss per common share (in thousands, except per share amounts): Year Ended December 31, 2025 2024 2023 Net loss per ImmunityBio common share – basic Numerator: Net loss attributable to ImmunityBio common stockholders $ ( 351,398 ) $ ( 413,564 ) $ ( 583,196 ) Denominator: Weighted-average number of common shares outstanding – basic 919,863 697,312 508,636 Net loss per ImmunityBio common share – basic $ ( 0.38 ) $ ( 0.59 ) $ ( 1.15 ) Net loss per ImmunityBio common share – diluted Numerator: Net loss attributable to ImmunityBio common stockholders $ ( 351,398 ) $ ( 413,564 ) $ ( 583,196 ) Add: Decrease in fair value of warrant liabilities — ( 19,921 ) — Numerator for net loss per ImmunityBio common share – diluted $ ( 351,398 ) $ ( 433,485 ) $ ( 583,196 ) Denominator: Weighted-average number of common shares outstanding – basic 919,863 697,312 508,636 Add: Dilutive effect of assumed exercise of “in-the-money” third-party warrants — 3,131 — Denominator for net loss per ImmunityBio common share – diluted 919,863 700,443 508,636 Net loss per ImmunityBio common share – diluted $ ( 0.38 ) $ ( 0.62 ) $ ( 1.15 ) Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted net loss per share. The following table details the number of shares of common stock underlying those securities that were excluded from the computation of weighted-average number of common shares outstanding – diluted (shares in thousands): As of December 31, 2025 2024 2023 Related-party convertible notes 93,053 93,053 162,472 Outstanding stock options 23,932 15,408 9,820 Outstanding RSUs 8,128 5,945 7,504 Outstanding related-party warrants 1,638 1,638 1,638 Outstanding third-party warrants 65,054 — 37,733 Total 191,805 116,044 219,167 234 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) The potentially dilutive securities shown in the table above exclude an option to purchase up to approximately $ 5.0 million of the company’s common stock pursuant to the SPOA entered in connection with the RIPA, as the exercise price cannot be determined until the date of exercise. See Note 13 “Revenue Interest Purchase Agreement” for more information. 22. Segment Information We operate in one operating segment, and therefore have one reportable segment, focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our CEO is the chief operating decision-maker of the company and manages and allocates resources to our operations on a company-wide basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future-period financial results, allocating resources, and setting incentive targets. The measure of segment performance is net income (loss) as reflected in the consolidated statement of operations. The CODM uses net income (loss) to allocate resources on a consolidated basis, which enables the CODM to assess both the overall level of resources available and optimize distribution of resources across functions, therapeutic areas, regions and research and development programs in line with our long-term corporate-wide strategic goals. As the company manages its assets on a consolidated basis, the measure of segment assets is total assets, as reflected in the consolidated balance sheet. In accordance with ASC 280, we provided information about customers that amount to 10% or more of our total revenue, see Note 2 “Summary of Significant Accounting Policies—Concentration of Major Customers” for more information. 235 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) Net loss for our reportable segment is as follows (in thousands): Year Ended December 31, 2025 2024 2023 Total revenue $ 113,288 $ 14,745 $ 622 Cost of sales 753 — — Gross profit 112,535 14,745 622 Operating expenses External research and development expense (including amounts with related parties) (1) 29,273 29,268 67,124 Internal research and development expense (including amounts with related parties): (2) Personnel-related costs 94,767 90,864 89,085 Equipment, depreciation, and facility costs 52,087 52,176 51,810 Other research and development costs 42,432 17,836 24,347 Total internal research and development expense 189,286 160,876 165,242 Total research and development expense (including amounts with related parties) 218,559 190,144 232,366 Selling, general and administrative (including amounts with related parties) 150,003 168,783 129,620 Impairment of intangible assets — — 886 Total operating expenses 368,562 358,927 362,872 Loss from operations ( 256,027 ) ( 344,182 ) ( 362,250 ) Other income (expense), net Interest and investment income, net 6,405 7,975 1,131 Interest expense (including amounts with related parties) ( 60,985 ) ( 114,670 ) ( 128,934 ) Interest expense related to revenue interest liability ( 51,540 ) ( 39,657 ) ( 264 ) Change in fair value of warrant liabilities 49,089 19,955 ( 47,600 ) Change in fair value of related-party convertible note ( 42,773 ) 43,472 ( 36,203 ) Change in fair value of derivative liabilities 6,398 13,477 — Loss on equity method investment — — ( 7,549 ) Other expense, net ( 2,174 ) ( 15 ) ( 2,223 ) Total other expense, net ( 95,580 ) ( 69,463 ) ( 221,642 ) Loss before income taxes and noncontrolling interests ( 351,607 ) ( 413,645 ) ( 583,892 ) Income tax benefit 135 — 40 Net loss ( 351,472 ) ( 413,645 ) ( 583,852 ) Net loss attributable to noncontrolling interests, net of tax ( 74 ) ( 81 ) ( 656 ) Net loss attributable to ImmunityBio common stockholders $ ( 351,398 ) $ ( 413,564 ) $ ( 583,196 ) _______________ (1) Our external research and development expense supports our various preclinical and clinical programs. (2) Our internal research and development expense includes payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of our research and development activities. 236 Table of Contents ImmunityBio, Inc. and Subsidiaries Notes to Consolidated Financial Statements (Continued) We generate a portion of our revenues from outside of the U.S. Information about our revenue by geographic region is as follows (in thousands): Year Ended December 31, 2025 2024 2023 U.S. $ 113,010 $ 14,214 $ 31 Europe 278 531 591 Total segment revenue $ 113,288 $ 14,745 $ 622 23. Subsequent Events Warrant Exercises Subsequent to December 31, 2025, institutional holders exercised a total of 15,524,768 warrants pursuant to the April 2025 Warrant agreement at an exercise price of $ 3.1010 per share resulting in the issuance of 15,524,768 shares of the company’s common stock for proceeds totaling $ 48.1 million. As of February 23, 2026, a total of 13,500,000 warrants remain outstanding under the April 2025 Warrant agreement. Amendment to the Second Amended and Restated Promissory Note On January 23, 2026, the company entered into a letter amendment to the second amended and restated promissory note (the “$ 505 million December 2024 Promissory Note”) with Nant Capital, LLC (the “note holder”), an entity affiliated with Dr. Soon-Shiong, the company’s Executive Chairman and Global Chief Scientific and Medical Officer. Pursuant to the letter amendment, the note holder may convert any portion of the outstanding principal amount of the $ 505 million December 2024 Promissory Note into fully paid and nonassessable shares of the company’s common stock at any time prior to the maturity date. Prior to the letter amendment, the $ 505 million December 2024 Promissory Note, the note holder could only convert the outstanding principal amount in full. No other changes were made in connection with the letter amendment. 237 Table of Contents ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE. None.